



**Protocol for the ProCare Trial: a Phase II randomised controlled trial of shared care for follow-up of men with prostate cancer.**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004972
Article Type:	Protocol
Date Submitted by the Author:	31-Jan-2014
Complete List of Authors:	Emery, Jon; University of Melbourne, General Practice and Primary Care Academic Centre Doorey, Juanita; University of Western Australia, School of Primary, Aboriginal and Rural Health Care Jefford, Michael; Peter MacCallum Cancer Centre, Medical Oncology King, Madeleine; University of Sydney, PsychoOncology Cooperative Research Group (PoCoG) Pirootta, Marie; University of Melbourne, General Practice and Primary Care Academic Centre Hayne, Dickon; Fremantle Hospital, Urology Department Martin, Andrew; University of Sydney, 7. NHMRC Clinical Trials Centre Trevena, Lyndal; University of Sydney, School of Public Health Lim, Tee; Royal Perth Hospital, Genesis Cancer Care Constable, Roger; Prostate Cancer Foundation of Australia, Hawks, Cynthia; Fremantle Hospital, Urology Department Hyatt, Amelia; Peter MacCallum Cancer Centre, Medical Oncology Hamid, Akhil; Royal Perth Hospital, Urology Department Violet, John; Peter MacCallum Cancer Centre, Radiation Oncology Department Gill, Suki; Peter MacCallum Cancer Centre, Radiation Oncology Department Frydenberg, Mark; Monash University, Department of Surgery Schofield, Penelope; Peter MacCallum Cancer Centre, Department of Cancer Experiences Research
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	General practice / Family practice, Health services research, Urology
Keywords:	Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Urological tumours < ONCOLOGY, PRIMARY CARE, Prostate disease < UROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Protocol for the ProCare Trial: a Phase II randomised controlled trial of shared care for follow-up**  
4 **of men with prostate cancer.**  
5

6 **Authors:** Jon Emery <sup>1,2</sup>, Juanita Doorey <sup>2</sup>, Michael Jefford <sup>3</sup>, Madeleine King <sup>4</sup>, Marie Pirotta <sup>1</sup>, Dickon  
7 Hayne <sup>5,6</sup>, Andrew Martin <sup>7</sup>, Lyndal Trevena <sup>8</sup>, Tee Lim <sup>9</sup>, Roger Constable <sup>10</sup>, Cynthia Hawks <sup>6</sup>, Amelia  
8 Hyatt <sup>11</sup>, Akhlil Hamid <sup>12</sup>, John Violet <sup>13</sup>, Suki Gill <sup>13</sup>, Mark Frydenberg <sup>14</sup>, Penelope Schofield <sup>11</sup>.  
9

10  
11  
12 Corresponding author: [jon.emery@unimelb.edu.au](mailto:jon.emery@unimelb.edu.au)  
13

14 **Abstract**

15 **Introduction**

16 Men with prostate cancer require long term follow-up to monitor disease progression and manage  
17 common adverse physical and psychosocial consequences of treatment. There is growing  
18 recognition of the potential role of primary care in cancer follow-up. This paper describes the  
19 protocol for a phase II multisite randomised controlled trial of a novel model of shared care for the  
20 follow-up of men after completing treatment for low-moderate risk prostate cancer.  
21  
22

23 **Methods and Analysis**

24 The intervention is a shared care model of follow-up visits in the first 12 months after completing  
25 treatment for prostate cancer with the following specific components: a survivorship care plan, GP  
26 management guidelines, register and recall systems, screening for distress and unmet needs and  
27 patient information resources. Eligible men will have completed surgery and/or radiotherapy for  
28 low-moderate risk prostate cancer within the previous eight weeks and have a GP who consents to  
29 participate. Ninety men will be randomised to the intervention or current hospital follow-up care.  
30 Study outcome measures will be collected at baseline, 3, 6 and 12 months and include anxiety,  
31 depression, unmet needs, prostate cancer-specific quality of life and satisfaction with care. Clinical  
32 processes and health care resource usage will also be measured. The principal emphasis of the  
33 analysis will be on obtaining estimates of the treatment effect size and assessing feasibility in order  
34 to inform the design of a subsequent phase III trial.  
35  
36

37 **Ethics and Dissemination**

38 Ethics approval has been granted by the University of Western Australia and from all hospital  
39 recruitment sites in Western Australia and Victoria. Results of this phase II trial will be reported in  
40 peer-reviewed publications and in conference presentations.  
41  
42

43 **Trial Registration**

44 Australian New Zealand Clinical Trial Registry ACTRN12610000938000  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of study

- This is the first randomised controlled trial of a model of shared care for men with prostate cancer;
- It is also the first trial to use the Distress Thermometer in primary care and the first to test a specific checklist to identify unmet needs of cancer survivors in primary care.
- As a phase II trial of a complex intervention it is designed to provide preliminary estimates of the feasibility and the efficacy of the shared care intervention for phase III planning purposes

### Introduction

Prostate cancer is the second most common cause of cancer among men worldwide, with the highest estimated incidence rates being in Australia and New Zealand, North America and western and northern Europe.<sup>1</sup> Age-standardised incidence rates in 2008 per 100,000 males were 104.2 in Australia and New Zealand; 93.1 in Western Europe and 85.6 in Northern America.<sup>2</sup> In Australia 19,438 men were newly diagnosed with prostate cancer in 2009<sup>3</sup> and the incidence is projected to increase to approximately 25,310 by 2020.<sup>4</sup> In the United States, there were an estimated 246,000 new prostate cancer cases in 2010 and this is projected to rise to 322,000 by 2020.<sup>5</sup> These changes in prostate cancer incidence are largely due to the growing use of the PSA as a screening test but also due to the ageing population.<sup>3</sup>

Although prostate cancer is a common cause of death from cancer, 5-year survival is relatively high. Between 2006 and 2010, the 5-year relative survival rate for men diagnosed with prostate cancer in Australia was 92%, with survival being highest for men aged 50 – 69 years.<sup>3</sup> Most recent data from the United States show a 5-year relative survival for prostate cancer of 99%.<sup>6</sup> Men who have completed treatment for prostate cancer require long term follow-up, to detect recurrence or progression of the disease, monitor any adverse effects of treatment and to identify and address any ongoing psychosocial needs.<sup>7</sup> Men with prostate cancer also frequently have a range of comorbid conditions requiring management.

#### *Prostate cancer: high burden of illness*

Observational studies from the USA and UK have demonstrated that men treated for prostate cancer frequently experience distressing and ongoing side-effects, most notably urinary and bowel incontinence, sexual dysfunction, and significant psychological issues.<sup>8,9</sup> The severity and duration of side effects vary by treatment modality. A recently published study from the United States of 1655 men treated for localised prostate cancer with 15 years follow-up found that men having a prostatectomy were more likely to have urinary incontinence and erectile dysfunction at 2 and 5 years post-treatment than those undergoing radiotherapy, but less likely to have bowel urgency.<sup>10</sup>

Research also demonstrates that following prostate cancer treatment the majority of men have unmet psychological and supportive care needs. A cross sectional survey of 1001 men with prostate cancer living in seven European countries found that 81% had some unmet supportive care needs, including psychological, sexual and health system and information needs.<sup>11</sup> In a population-based cohort of 978 Australian men with recently treated prostate cancer, 54% had unmet psychological needs, particularly 'uncertainty about the future' (21%) and 47% unmet sexual needs.<sup>12</sup> A larger

1  
2  
3 Australian longitudinal study with three year follow-up compared men treated for prostate cancer  
4 with matched controls to account for potential effects of normal ageing. Men treated for prostate  
5 cancer had lower sexual function, especially those on androgen deprivation therapy (97% impotence  
6 at 3 years) , compared with 53% under active surveillance.<sup>13</sup> At three years, 67.9% of men who had  
7 nerve sparing radical prostatectomy and 86.7% of men who had non-nerve sparing radical  
8 prostatectomy were impotent. Men treated with radical prostatectomy reported worst urinary  
9 function (16% incontinence at 1 year, 12% at 3 years) compared with 3% incontinence after 3 years  
10 in the active surveillance group; and bowel function was worst in those receiving external beam  
11 radiotherapy (15% moderate or severe bowel problems at 3 years; compared with 3% after 3 years  
12 of active surveillance.)  
13

#### 14 *Current care of men with prostate cancer in general practice*

15 The role of general practitioners (GPs) in prostate cancer screening is well recognised. General  
16 practice is also heavily engaged in managing men with prostate cancer including long term  
17 treatment and related health problems. Longitudinal data from the United Kingdom on nearly 5000  
18 prostate cancer survivors (5 years or longer post diagnosis) found that these men consulted their GP  
19 up to three more times annually compared to controls, a trend that continued even 15 years after  
20 diagnosis.<sup>14</sup> Compared to matched controls, prostate cancer survivors had 39% more consultations  
21 over a 3-year follow-up period, partly due to monitoring and administration of hormonal treatments.  
22 Data from the Netherlands also showed that prostate cancer patients consult their GP more than  
23 controls at 2–5 years after diagnosis, for both cancer-related health problems and chronic disease  
24 management.<sup>15</sup>  
25  
26  
27

28 In Australia, data from the Bettering the Evaluation and Care of Health (BEACH) study showed that,  
29 of 2,385 general practice consultations about prostate cancer in 2008 only 9% were for prostate  
30 cancer as a new problem(personal communication).<sup>16</sup> The following services were provided: PSA test  
31 request (21%); counselling, advice and education (15%); local injection / implant insertion (12%);  
32 prescription, predominantly for opioids and anti-androgens (approximately 30%); and referral,  
33 predominantly to urology or oncology (10%).  
34

35 An expanded role for primary care in the follow-up of people with cancer is increasingly seen as  
36 critical for long term sustainability of the health system in many developed nations.<sup>17 18</sup> This is  
37 recognised in UK's National Cancer Survivorship Initiative<sup>19</sup> and, specifically in relation to prostate  
38 cancer, by the National Institute for Health and Clinical Excellence.<sup>20</sup>  
39  
40  
41

42 A systematic review of primary care based follow-up in trials with breast and colon cancer survivors  
43 found no statistically significant differences between primary and secondary care follow up in terms  
44 of patient wellbeing, psychological morbidity, and patient satisfaction.<sup>21</sup> A randomised controlled  
45 trial of GP-led follow-up of people with melanoma found no significant difference in health status or  
46 anxiety and depression between intervention and control groups. However, there were significant  
47 improvements in some aspects of patient satisfaction with care for those receiving GP-led melanoma  
48 follow-up.<sup>22</sup> A recent rapid review of the evidence reported on seven trials of shared care in cancer;  
49 most of these focused on increasing the primary care team's involvement in managing symptoms  
50 during or immediately following treatment for cancer.<sup>23 24</sup> These trials found that shared care  
51 models of cancer follow-up can improve a range of important process outcomes including patient  
52 and provider satisfaction, provider confidence and knowledge, and patient perceptions of care. No  
53 trials of shared care have tested a structured approach to sharing cancer surveillance, management  
54 of treatment-related effects and psychosocial support between hospital and primary care after  
55 completion of treatment. Furthermore, there are no trials reported to date of prostate cancer  
56 follow-up in primary care.  
57  
58  
59  
60

1  
2  
3  
4 Previous trials of primary care follow-up have focused on detection of recurrence to the exclusion of  
5 the multiple needs and co-morbidities of patients which may be more appropriately dealt with from  
6 a generalist perspective.<sup>23 25</sup> The key elements in a conceptual model of generalism include  
7 accessibility, holistic patient-centred, team-based care, care coordination, continuity and  
8 management of complex multiple problems.<sup>26</sup> Evidence from previous studies with cancer survivors  
9 followed up in primary care suggest that they are more likely to receive preventive interventions for  
10 conditions other than cancer, whereas those followed up by oncologists are more likely to receive  
11 interventions directed at cancer surveillance.<sup>27</sup> Primary care may therefore have an important  
12 broader generalist role to play in cancer follow-up.  
13

#### 14 *Principles underpinning a novel shared care model of follow-up for prostate cancer*

15 In 2005, the US Institute of Medicine (IOM) released a landmark report From Cancer Patient to  
16 Cancer Survivor: Lost in Transition.<sup>28</sup> The report recommended that new research initiatives focused  
17 on cancer patient follow-up were urgently needed to guide effective survivorship care. The IOM  
18 report outlined four essential components of survivorship care planning:

19 (1) prevention of recurrent and new cancers, and of other late effects; (2) surveillance for cancer  
20 spread, recurrence, or second cancers; assessment of medical and *psychosocial* late effects; (3)  
21 interventions for consequences of cancer and its treatment; and (4) coordination between  
22 specialists and primary care providers to ensure that all of the survivor's health needs are addressed.  
23  
24

25 The most common systemic problems in providing comprehensive cancer care include requirement  
26 for a case manager, local accessible health services and doctors who communicate with each  
27 other.<sup>29</sup> A systematic review of guidelines for follow-up care in prostate cancer highlighted that  
28 most focus on the detection of cancer recurrence and assessment of the medical consequences of  
29 treatment, with little attention placed on identifying and responding to other key unmet needs.<sup>30</sup>  
30  
31

32 In the ProCare Trial we are applying the following principles to guide the design of a model of shared  
33 hospital and primary care for prostate cancer.  
34

#### 35 *a. Communication between hospital and primary care.*

36 A current major issue in cancer follow-up is coordination of care between specialists and general  
37 practice, partly due to out-dated approaches to communication. Timely and systematic  
38 communication between hospital and community care providers is urgently required to clarify the  
39 roles and responsibilities of all, including the person with cancer.<sup>31 32</sup> An Australian trial comparing  
40 methods of communication between hospital and general practices found that fax had higher  
41 receipt rates than post and was the most preferred method by GPs.<sup>33</sup> An innovative trial of  
42 electronic faxing of standardised information to GPs about a patient's chemotherapy regime has  
43 shown that this approach led to improved GP confidence in managing adverse effects of treatment  
44 and increased satisfaction with shared care.<sup>34</sup> Survivorship care plans (SCPs) are recommended as  
45 an important tool to facilitate communication and clarify responsibility during the transition from  
46 active treatment to survivorship.<sup>27</sup> There has only been one trial of the use of SCPs in primary care<sup>35</sup>  
47 but several methodological issues have been raised about this trial which may explain its negative  
48 findings<sup>36</sup> so further evidence is needed.  
49  
50

#### 51 *b. Promotion of patient involvement and engagement.*

52 Cancer patients want to be involved with decision-making, and wish to participate in strategies to  
53 remain well.<sup>37</sup> Involving patients with chronic diseases in their disease management results in better  
54 communication with physicians, improved self-reported health and reduced health distress, few  
55 hospitalisations and reduced health costs.<sup>38 39</sup> Self-management approaches also have potential for  
56 ameliorating the functional and emotional problems experienced by prostate cancer survivors.<sup>40</sup> A  
57  
58  
59  
60

systematic review of patient activation approaches has shown they can alter the content of consultations and improve the identification of patients' concerns.<sup>41</sup> Approaches that allow patients to list and share their concerns with their doctor, particularly if linked to practitioner interventions, showed particular promise in this review. A separate systematic review of problem checklists found that these can empower cancer patients to ask relevant questions in healthcare consultations.<sup>42</sup>

*c. Tailoring care to specific needs of individual patients.*

Cancer survivors have different needs.<sup>29 43</sup> Therefore, interventions need to be systematically tailored to each individual. A review of tailored versus standardised information interventions in the health promotion area found that tailored interventions were significantly more effective in promoting health behaviour outcomes.<sup>44</sup> A randomised controlled trial with 543 prostate and breast cancer survivors tested the efficacy of sequentially tailored versus standardised materials on improving diet and exercise behaviours and found that those receiving tailored materials had improved lifestyle behaviours.<sup>45</sup>

### **Aims of the ProCare Trial**

The ProCare Trial is a phase II trial of a multifaceted intervention designed to: 1) be patient-centred by eliciting individual needs and assisting patients to direct their health care; 2) provide appropriate multidisciplinary referrals and tailored information to patients; 3) provide holistic care coordination by a GP to address the multifaceted physical, psychosexual and social needs of men with prostate cancer; and 4) improve the timeliness and content of communication between hospital and primary care.

The trial is set within the Medical Research Council framework for the development and evaluation of complex interventions.<sup>46 47</sup> The objectives of this phase II trial reflect the need to optimise the intervention, establish acceptability of the intervention and randomisation, confirm suitability of outcome measures and provide estimates of efficacy, and recruitment and attrition rates to allow planning of a larger phase III trial. It therefore does not specifically employ a statistical hypothesis-testing framework.

### **Methods and Analysis**

#### *Trial design and randomisation*

A phase I study that operationalised the different components of the intervention and explored clinical feasibility and acceptability has been completed. Eleven men who met the eligibility criteria were recruited from two hospitals in Perth, Western Australia, with all receiving the intervention and completing the outcome measures throughout the 12 months of follow-up. Participants were interviewed by telephone after each of their three GP visits, with the interview data demonstrating acceptability of the intervention. Issues pertaining to the intervention and the outcome measures have been addressed and incorporated into the Phase II trial.

The phase II trial is a multi-site randomised controlled trial. Men who meet the eligibility criteria and who consent to participate are randomised 1: 1 to either usual care (control arm) or to trial shared-care (intervention arm). Randomisation is being performed using a centralised independent tele-randomisation system managed by the NHMRC Clinical Trials Centre, based at the University of Sydney. Stratifying variables for randomisation are hospital site and treatment type.

#### *Population and setting*

Men are being recruited from one rural and three urban public treatment centres in two Australian states (Western Australia and Victoria); private patients are also being recruited from one centre in Victoria.

### *Inclusion criteria*

1. Pathologically confirmed prostate cancer.
2. Completed surgery and / or radiotherapy (brachytherapy or external beam, and which may also include neo-adjuvant androgen deprivation therapy) with curative intent; study entry within 8 weeks post-operatively or 3 weeks after completion of radiotherapy.
3. Able to read and write English at a level sufficient to give informed consent and complete study procedures including written questionnaires without an interpreter.
4. Have a GP who agrees to participate in the trial.

### *Exclusion criteria*

1. Suspicion or evidence of metastatic disease.
2. Severe psychiatric or cognitive disorder, which in the opinion of the investigator would compromise participation the study.
3. Treatment with palliative intent.
4. No GP.
5. Patients with a pathologically confirmed diagnosis of prostate cancer with any of the following high risk features (cT3; Prostate Specific Antigen (PSA) >20 or Gleason score  $\geq$  8).
6. Patients having androgen deprivation therapy following radiotherapy, irrespective of risk level.

Minimal data will be completed with consent from eligible men who decline to participate to measure selection bias.

### *Participant and GP recruitment procedures*

Men receiving radiotherapy treatment are approached about the trial towards the end of their treatment, whilst men having surgery are approached once their histopathology results are confirmed. If men consent to participate, their GP is faxed trial information and a consent form. If their GP agrees to participate, the patient is formally enrolled in the trial and randomised. If the GP declines, the patient receives standard hospital follow-up care outside the trial. GPs are eligible to have more than one patient in the trial regardless of treatment allocation.

### *Intervention*

The intervention is based on a shared care model where two of the five routine hospital visits during the first 12 months of follow-up are replaced by GP visits. An additional GP visit shortly after the completion of their treatment for prostate cancer is intended to re-engage the patient with their GP (Table 1).

In addition to the altered schedule of follow-up, the following specific components of the intervention are designed to support the model of shared care:

1. Structured systematic communication, using a Survivorship Care Plan.
2. GP clinical management guidelines.
3. Register and recall system for follow-up appointments.
4. Screening for distress and unmet needs using the Distress Thermometer and Problem Checklist.<sup>48</sup>

## 5. Provision of patient information resources

### *Survivorship care plan*

A tailored survivorship care plan using information from the patient's hospital notes is developed at the end of treatment by a member of the research team. It is produced using an electronic template and includes information on: prostate cancer diagnosis and treatment history; treatment team and contact details for rapid access and advice; the schedule of follow-up visits and tests for recurrence; early and later side effects of treatment applicable to treatment modality; information on relevant local services and resources including the Cancer Council Helpline, prostate cancer support groups, and stress management and relaxation programs.

A draft of the care plan is discussed with the patient by telephone by one of the research team before their initial GP visit allowing additional information to be incorporated such as current adverse effects of treatment. The finalised care plan is provided to the patient, their GP and hospital specialist. The care plan is faxed to the GP before the first follow-up visit and is designed to be incorporated into the patient's GP medical record.

### *GP management guidelines*

GP management guidelines, based on international and local guidelines,<sup>49 50</sup> are included in the GP's copy of the care plan. They include guidelines on frequency of PSA testing and digital rectal examination to detect and manage recurrence, management of common physical and psychosexual adverse treatment effects, interpretation of the Distress Thermometer, and referral information to relevant services (e.g. sexual health and continence services).

### *Register and recall system*

This is a well-established component of good chronic disease management to reduce loss to follow-up and implement timely care.<sup>51</sup> A reminder letter is sent by the research team to the patient to attend each follow-up appointment, either at the hospital or general practice. Reminder letters are sent to GPs before the six and nine month visits.

### *Screening for distress and concerns*

The Distress Thermometer (DT) is a widely used validated screening tool for assessing psychological distress in people affected by cancer.<sup>48</sup> Men complete the Distress Thermometer on the day of each GP visit and GPs are advised to explore the meaning of distress and consider depression or anxiety in men with a cut-off score of four or greater. A modified problem checklist, specific to prostate cancer, has been incorporated into the DT, and covers physical and psychosocial issues. Men are asked to tick any problems they have experienced in the previous week, identifying the three most important. They give the checklist to their GP at the beginning of the consultation, to shape the content of the consultation and to facilitate discussion of specific unmet needs.

### *Patient information resources*

In addition to the information within the survivorship care plan, patients are offered the following prostate cancer specific information, according to their specific circumstances:

Localised prostate cancer: a guide for men and their families (Cancer Council Australia 2010, 4<sup>th</sup> edition);

Continence and prostate: A guide for men undergoing prostate surgery; (Continence Foundation of Australia, 2008)

Treat ED: prostate edition. Understanding the impact of prostate cancer treatment on erectile function (Eli Lilly Australia)



Maintaining your well-being: Information on depression and anxiety for men with prostate cancer and their partners (beyond blue in association with Prostate Cancer Foundation of Australia).

### Control group

Men in the control group receive clinical care according to current hospital practice with frequency of visits as outlined in Table 1, consistent with current international guidelines.<sup>50</sup>

### Outcomes and measures

As a phase II trial we have not determined a single primary outcome measure but instead are applying a battery of established instruments to measure the effects of the various components of this complex intervention.<sup>47</sup> This will inform decisions about outcome measures for a future phase III trial.

*Demographics and clinical variables* include: age, postcode, marital status, education level and occupation, treatment type, diagnosis, stage of disease and patient reported co-morbidities.

#### *Patient-reported outcome measures*

*Psychological Distress: Hospital Anxiety and Depression Scale (HADS)*<sup>52</sup>. This 14-item scale has been widely used to measure distress in people with cancer; it has been extensively validated and shown to perform well in a wide range of populations (Cronbach  $\alpha = 0.82$ ; sensitivity and specificity 0.80).<sup>53</sup> A systematic review of measures of distress in cancer patients has concluded that the HADS performs better than other similar measures.<sup>54</sup>

*Survivors' unmet needs: Cancer Survivors' Unmet Needs measure (CaSUN)* This 35-item scale assesses unmet needs across information, patient care, psychosocial, physical and sexual domains.<sup>55</sup> The scale has good acceptability, internal consistency (Cronbach  $\alpha = 0.96$ ) and construct validity. Due to difficulties with the response format experienced by some participants in the phase I study, a simplified four-point response format is being used in this trial (no, low, moderate and high need).<sup>56</sup>

*Quality of Life: Expanded Prostate Cancer Index Composite (EPIC)* assesses prostate-specific quality of life (32 items with 4 subscales: urinary, bowel, sexual and hormonal function). It has greater coverage of key domains and sensitivity to treatment effects than previous prostate-specific quality of life measures.<sup>57</sup> It shows good test-retest reliability and internal consistency for all domain summary scores (each  $r > 0.80$  and Cronbach's  $\alpha > 0.82$ ).

*The Short-form Patient Satisfaction Questionnaire (PSQ-18)* consists of 18 items covering access, convenience, continuity, perceived communication between healthcare providers and technical competence).<sup>58</sup> It shows good internal consistency (each Cronbach's  $\alpha > 0.7$ ) and strong correlations with the original 50-item PSQIII.<sup>59</sup> After piloting in the phase I study, this scale has been modified to refer explicitly to the cancer follow-up care provided by hospital doctors and general practitioners during the previous 12 months.

*Preference for Follow-up Care (PFC)* Questions about preferences for future follow-up care have been adapted from the Cancer Survivors Follow-up Care Study (Adult Survivors Survey; personal communication A Girgis) A direct question about preference for specific type of follow-up care has also been included.

Participants complete the HADs, CaSUN and EPIC at four time points: prior to randomisation and then at 3, 6 and 12 months follow-up. Participants complete the PSQ-18 and PFC after their 12 month follow-up appointment.

#### *Clinical process measures*

The following clinical information will be collected from GP medical records and Medicare Australia data, including both Medical Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) data:

- a. Recurrence rates and detection: use of PSA according to protocol<sup>50</sup> and time to detect recurrence.
- b. Mental health care: e.g. prescribing of antidepressants; referrals to clinical psychologists and use of specific Medicare Mental Health Care Plan items.
- c. Detection and management of psychosexual adverse effects: e.g. prescribing of phosphodiesterase type-5 inhibitors and referrals to sexual health services.
- d. Detection and management of other physical adverse effects of treatment: prescribing pre-specified drugs for urinary and bowel symptoms (e.g. oxybutynin, prazosin, loperamide, steroid enemas) and referrals to continence physiotherapy or urology.
- e. Management of co-morbidities will be determined by pathology data for common tests performed in the management of common chronic disease (e.g. vascular disease and diabetes) and will include, for example, lipids and HbA1c. This is to assess whether the model of shared care has an effect on the management of other co-morbidities.

*Health care resource usage:* data will be collected regarding hospitalisations, visits to healthcare professionals, investigations and medications, predominantly through Medicare Australia (MBS and PBS) and GP record audit. Unit costs obtained from a variety of sources (e.g. Australian refined diagnosis-related groups, MBS and PBS) will be applied to the resource usage data collected within the trial to estimate the incremental cost of the shared care model versus standard care from a health service perspective.

*Trial feasibility:* as a phase II trial we will obtain data on patient eligibility, recruitment and attrition rates, GP recruitment and attrition rates, and response rates to outcome measures to inform decisions and planning for a larger phase III trial.

#### *Sample size*

The study is designed to provide preliminary estimates of the feasibility and the efficacy of the shared care intervention for phase III planning purposes and does not employ a statistical hypothesis testing framework. The sample size is based on ensuring adequate information is collected to yield preliminary estimates of the treatment effect and of between-patient variation that are sufficiently precise for phase III trial planning purposes. The sample size target was revised at a steering committee meeting on 02 August 2012. This was in response to lower accrual rates than predicted, specifically due to a lower proportion of low-moderate risk prostate cancers than originally estimated. The revised target of 90 men was selected to ensure that the 95% confidence intervals for the mean difference between the two groups on the patient reported outcome measures would extend no further than +/- 0.5 of a standard deviation with 80% probability and allowing for 10% attrition at 12 months (i.e. complete data on N = 80 is required). This level of precision corresponds

to what has been proposed as a minimal clinically important difference of health-related quality of life measures<sup>60</sup> allowing us to identify clinically significant harm from the intervention if it existed. Data from a trial of a group-based intervention involving 331 men with prostate cancer in Victoria, Australia (P Schofield, in submission) has been used to estimate how this level of precision will translate to estimates from the HADS and EPIC instruments.

Recruitment was completed in July 2013.

### Analyses

Baseline characteristics of the two arms will be described. Possible attrition bias will be assessed by comparing non-completion rates between treatment groups in conjunction with the baseline characteristics of those who withdraw or die against those who remain in the study.

*Estimating potential effect size and coefficient of variation:* Mean scores of HADS, CaSUN, EPIC and PSQ-18 will be compared between intervention and usual care groups. Mean differences between groups will be calculated with 95% confidence intervals at each follow-up time-point with and without adjusting for baseline score, site and treatment type (surgery and / or radiotherapy). Treatment groups will be compared on the categorical endpoints (e.g. clinical process measures) using chi-squared tests. Logistic regression modelling will also be undertaken to estimate the treatment effect on these endpoints adjusting for baseline covariates. The principal emphasis of the analysis will be on obtaining estimates of the treatment effect size and assessing feasibility in order to inform the design of a subsequent phase III trial. P-values for the multiple comparisons between the groups will be interpreted in this context.

### Discussion

The ProCare Trial has several novel elements: it is the first randomised controlled trial of a model of shared care for men with prostate cancer; it is the first trial to use the Distress Thermometer in primary care and the first to test a specific problem checklist to identify unmet needs of cancer survivors in primary care. We are testing a survivorship care plan (SCP) in primary care. One of the problems with the Grunfeld trial of SCPs in primary care was the high proportion of prevalent cancer cases who had completed treatment several years previously, and were possibly less likely to benefit.<sup>35 36</sup> We are therefore only recruiting men who have very recently completed their cancer treatment and in their first 12 months of follow-up care.

As a phase II trial it is designed to yield estimates of sufficient precision for phase III trial planning purposes. However, as with all trials of alternative models of cancer follow-up, an outstanding methodological issue is the selection of an appropriate primary outcome measure. Most trials have measured satisfaction with care and a range of health-related quality of life measures, finding no differences between hospital and primary care follow-up.<sup>23</sup> Trials in populations at low risk of cancer recurrence would need to be unfeasibly large to detect differences in survival. The ProCare Trial includes a range of outcome measures including disease-specific quality of life and unmet need. The intervention is designed to improve the identification of unmet needs and implement best practice management in the expectation that this will improve disease-specific quality of life and overall well-being.

We are recruiting men from a range of metropolitan and rural settings in two states in Australia including public and private healthcare settings. Based on discussions with urologists and radiation oncologists we have chosen only to recruit men with low-intermediate risk of disease recurrence, based on the D'Amico criteria.<sup>61</sup> As the first trial of shared follow-up care in prostate cancer it was agreed by the investigator team for safety reasons to focus initially on men with low-intermediate risk disease. This is also consistent with international approaches to risk stratified follow-up.<sup>62</sup> Our

trial population is likely to be representative of a wide range of men with low-intermediate risk prostate cancer who might be offered alternative follow-up arrangements if this model of care were shown to be feasible and acceptable.

We plan to complete follow-up in July 2014 and report trial results in early 2015.

### Ethics

Ethics approval has been granted from the University of Western Australia's Human Research Ethics Committee (RA / 4/ 1/ 4447) as well as from all hospital recruitment sites in Western Australia and Victoria. The study has also been approved by the External Review Committee of the Commonwealth Department of Human Services to obtain Medicare Benefits Schedule and Pharmaceutical Benefits Schedule data from participants with their consent.

### Dissemination

This is the first randomised controlled trial of a model of shared care for men with prostate cancer; it is also the first trial to use the Distress Thermometer in primary care and the first to test a specific checklist to identify unmet needs of cancer survivors in primary care. We plan to publish the main trial outcomes in a single paper and anticipate publishing additional papers exploring the data in more detail and relating to the implementation of this complex intervention. We will also present the findings at national and international conferences from late 2014.

### Author affiliations

1. General Practice and Primary Health Care Academic Centre, The University of Melbourne
2. General Practice, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia
3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria
4. Psycho-oncology Co-operative Research Group (PoCoG), School of Psychology, The University of Sydney
5. School of Surgery, The University of Western Australia
6. Urology Department, Fremantle Hospital, Western Australia
7. NHMRC Clinical Trials Centre, Sydney Medical School, The University of Sydney
8. School of Public Health, The University of Sydney
9. Genesis Cancer Care, Royal Perth Hospital, Western Australia
10. Prostate Cancer Foundation of Australia
11. Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria
12. Urology Department, Royal Perth Hospital, Western Australia
13. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria
14. Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University

### Contributors

JE coordinated the design, funding award and implementation of the study and led the writing of the manuscript;

JD coordinated the recruitment and data collection for the study and contributed to the writing of the manuscript;

MJ contributed to the design, funding award and implementation of the study and to the writing of the manuscript;

MK contributed to the design, funding award and implementation of the study and to the writing of the manuscript;

1  
2  
3 MP contributed to the study design, funding award and implementation of the study and to the  
4 writing of the manuscript;  
5 DH contributed to the study design, funding award and implementation of the study in WA and  
6 contributed to the writing of the manuscript;  
7 AM contributed to the study design, funding award and statistical advice and contributed to the  
8 writing of the manuscript;  
9 LT contributed to the design, funding award and implementation of the study and to the writing of  
10 the manuscript;  
11 TL provided clinical expertise and was principal investigator at Royal Perth Hospital recruitment site;  
12  
13  
14 RC provided expertise from consumer perspective for study design, funding award and  
15 implementation of the study.  
16 CH undertook recruitment and data collection at Fremantle Hospital, WA  
17 AmH undertook recruitment and data collection for Victorian sites  
18 AkH was principal investigator at Royal Perth Hospital Urology Services, WA  
19 JV was principal investigator at Peter MacCallum Cancer Centre, Sunshine Hospital, Victoria  
20 SG was principal investigator at Peter MacCallum Cancer Centre, Bendigo Hospital, Victoria  
21 MF was principal investigator at Cabrini Hospital and Bairnsdale Hospital, Victoria  
22 PS contributed to the study design, funding award and implementation of the study in Victoria and  
23 to the writing of the manuscript.  
24  
25  
26

### 27 **Funding**

28 This trial is supported by the National Health and Medical Research Council (grant ID 1003414).  
29 Associate Professor Schofield and Associate Professor Pirotta are supported by National Health and  
30 Medical Research Council Career Development Fellowships.  
31

### 32 **Competing interests**

33 None  
34

### 35 **Acknowledgements**

36 This trial is supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group  
37 (PC4) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).  
38

39 We thank the following people who have also been involved in the establishment and conduct of  
40 this trial: Sharon Ray, Sema Cakan, Anna Ugalde, Rose Kamateros, Emily Habgood, Danielle Miller  
41 and Shona Silvester.  
42

43 We are grateful to all the trial participants, GPs and hospital specialists involved in the trial.  
44  
45  
46

### 47 **References**

- 48 1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in  
49 prostate cancer incidence and mortality rates. *European urology* 2012;61(6):1079-92.
- 50 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of  
51 cancer in 2008: GLOBOCAN 2008. *International journal of cancer. Journal international du*  
52 *cancer* 2010;127(12):2893-917.
- 53 3. Cancer in Australia: an overview. Canberra: Australian Institute of Health and Welfare, 2012.
- 54 4. Cancer incidence projections: Australia, 2011-2020. Canberra: Australian Institute of Health and  
55 Welfare, 2012.  
56  
57  
58  
59  
60

5. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009;27(17):2758-65.
6. SEER Stat Fact Sheets: Prostate Cancer: National Cancer Institute, 2013.
7. O'Brien R, Rose PW, Campbell C, Weller D, Neal RD, Wilkinson C, et al. Experiences of follow-up after treatment in patients with prostate cancer: a qualitative study. *BJU International* 2010;106(7):998-1003.
8. Boberg E, Gustafson D, Hawkins R, Offord K, Koch C, Wen K. Assessing the unmet information, support and care delivery needs of men with prostate cancer. *Patient Educ Counsel* 2003;49:233-42.
9. Ream E, Quennell A, Fincham L, Faithfull S, Khoo J, Wilson-Barnett J. Supportive care needs of men living with prostate cancer in England: a survey. *British Journal of Cancer* 2008;98:1903-09.
10. Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, et al. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. *New England Journal of Medicine* 2013;368(5):436-45.
11. Cockle-Hearne J, Charnay-Sonnek F, Denis L, Fairbanks HE, Kelly D, Kav S, et al. The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. *British journal of cancer* 2013;109(8):2121-30.
12. Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer. *J Clin Oncol* 2007;25(18):2560-6.
13. Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. *BMJ* 2009;339:b4817.
14. Khan NF, Watson E, Rose PW. Primary care consultation behaviours of long-term, adult survivors of cancer in the UK. *British Journal of General Practice* 2011;61(584):197-99.
15. Heins MJ, Korevaar JC, Rijken PM, Schellevis FG. For which health problems do cancer survivors visit their General Practitioner? *European journal of cancer* 2013;49(1):211-18.
16. The BEACH Project: Bettering the Evaluation and Care of Health Australian General Practice Statistics and Classification Centre, 2009.
17. Role Redesign Primary Care – Shared Care. Models of Cancer Treatment and Surveillance Post Treatment. Final Report. . In: Communications. GCa, editor. Canberra: Cancer Australia, 2010.
18. Pascoe SW, Neal RD, Allgar VL, Selby PJ, Wright EP. Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. *Fam Pract* 2004;21(4):437-42.
19. Richards M, Corner J, Maher J. The National Cancer Survivorship Initiative: new and emerging evidence on the ongoing needs of cancer survivors. *British journal of cancer* 2011;105 Suppl 1:S1-4.
20. Prostate cancer: diagnosis and treatment. London: National Institute of Clinical Excellence, 2008.
21. Lewis RA, Neal RD, Williams NH, France B, Hendry M, Russell D, et al. Follow-up of cancer in primary care versus secondary care: systematic review. *The British journal of general practice : the journal of the Royal College of General Practitioners* 2009;59(564):e234-47.
22. Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. *British journal of cancer* 2010;102(10):1447-55.
23. Emery JD, Trevena L, Mazza D, Fallon-Ferguson J, Shaw K, Williams B, et al. The role of primary and community-based healthcare professionals in early detection and follow-up of cancer: a rapid review of best practice models. Sydney, NSW: Sax Institute, 2013.
24. Emery JD, Shaw K, Williams B, Mazza D, Fallon-Ferguson J, Varlow M, et al. The role of primary care in early detection and follow-up of cancer. *Nature reviews. Clinical oncology* 2014;11(1):38-48.

25. Taggart F, Donnelly P, Dunn J. Options for early breast cancer follow-up in primary and secondary care - a systematic review. *BMC cancer* 2012;12:238.
26. Gunn JM, Palmer VJ, Naccarella L, Kokanovic R, Pope CJ, Lathlean J, et al. The promise and pitfalls of generalism in achieving the Alma-Ata vision of health for all. *Med J Aust* 2008;189(2):110-2.
27. Grunfeld E, Earle C. The Interface Between Primary and Oncology Speciality Care: Treatment Through Survivorship. *J Natl Cancer Inst. Monographs* 2010(40):25-30.
28. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington DC, 2006.
29. Hodgkinson K, Butow P, Hobbs KM, Wain G. After cancer: the unmet supportive care needs of survivors and their partners. *J Psychosoc Oncol* 2007;25(4):89-104.
30. McIntosh HM, Neal RD, Rose P, Watson E, Wilkinson C, Weller D, et al. Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. *Br J Cancer* 2009;100(12):1852-60.
31. Jiwa M, Saunders CM, Thompson SC, Rosenwax LK, Sargant S, Khong EL, et al. Timely cancer diagnosis and management as a chronic condition: opportunities for primary care. *Med J Aust* 2008;189(2):78-82.
32. Walsh J, Harrison JD, Young JM, Butow PN, Solomon MJ, Masya L. What are the current barriers to effective cancer care coordination? A qualitative study. *BMC Health Services Research* 2010;10.
33. Chen Y, Brennan N, Magrabi F. Is email an effective method for hospital discharge communication? A randomized controlled trial to examine delivery of computer-generated discharge summaries by email, fax, post and patient hand delivery. *Int J Med Inform.*
34. Jefford M, Baravelli C, Dudgeon P, Dabscheck A, Evans M, Moloney M, et al. Tailored chemotherapy information faxed to general practitioners improves confidence in managing adverse effects and satisfaction with shared care: results from a randomized controlled trial. *J Clin Oncol* 2008;26(14):2272-7.
35. Grunfeld E, Julian J, Pond G, Maunsell E, Coyle D, Folkes A, et al. Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. *Journal of Clinical Oncology* 2011;29(36):4755-62.
36. Jefford M, Schofield P, Emery J. Improving survivorship care. *Journal of Clinical Oncology* 2012;30(12):1391-92.
37. Brown RF, Butow PN, Sharrock MA, Henman M, Boyle F, Goldstein D, et al. Education and role modelling for clinical decisions with female cancer patients. *Health Expect* 2004;7(4):303-16.
38. Barlow J, Wright C, Sheasby J. Self-management approaches for people with chronic conditions: a review. *Patient Educ Counsel* 2002;48:177-87.
39. Deadman J, Leinster S, Owens R. Taking responsibility for cancer treatment. *Soc Sci Med* 2001;53:669-77.
40. Cockle-Hearne J, Faithfull S. Self-management for men surviving prostate cancer: a review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. *Psycho-oncology* 2010;19(9):909-22.
41. Griffin SJ, Kinmonth AL, Veltman MW, Gillard S, Grant J, Stewart M. Effect on health-related outcomes of interventions to alter the interaction between patients and practitioners: a systematic review of trials. *Ann Fam Med* 2004;2(6):595-608.
42. Dimoska A, Tattersall MH, Butow PN, Shepherd H, Kinnorsley P. Can a "prompt list" empower cancer patients to ask relevant questions? *Cancer* 2008;113(2):225-37.
43. Jefford M, Karahalios A, Angle A. Understanding issues for cancer survivors: informing the development of a written information booklet. *Psychooncology* 2007;16 S273.
44. Ryan P, Lauver DR. The efficacy of tailored interventions. *J Nurs Scholarsh* 2002;34(4):331-7.
45. Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, et al. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention

- 1  
2  
3 among breast and prostate cancer survivors. *Journal of clinical oncology : official journal of*  
4 *the American Society of Clinical Oncology* 2007;25(19):2709-18.
- 5 46. Developing and evaluating complex interventions: new guidance. London: Medical Research  
6 Council., 2008.
- 7 47. Campbell N, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F, et al. Designing and evaluating  
8 complex interventions to improve healthcare. *BMJ* 2007;334:455-59.
- 9 48. Jacobsen P, Donovan K, Trask P. Screening for psychologic distress in ambulatory care patients.  
10 *Cancer* 2005;103:1494-502.
- 11 49. Localised prostate cancer: a guide for men and their families. : Andrology Australia & Australian  
12 Prostate Cancer Collaboration. , 2009.
- 13 50. Heidenreich A, Bolla M, Joniau S, Kwast THvd, V. Matveev, Mason MD, et al. Guidelines on  
14 prostate cancer: European Association of Urology, 2009.
- 15 51. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving Chronic Illness  
16 Care: Translating Evidence Into Action. *Health Affairs* 2001;20:64-78.
- 17 52. Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*  
18 1983;67:361-70.
- 19 53. Bjellanda I, Dahlb A, Haugc T, Neckelmann D. The validity of the Hospital Anxiety and Depression  
20 Scale. An updated literature review. *Journal of Psychosomatic Research* 2002; 52:69- 77.
- 21 54. Lockett T, Butow PN, King MT, Oguchi M, Heading G, Hackl NA, et al. A review and  
22 recommendations for optimal outcome measures of anxiety, depression and general distress  
23 in studies evaluating psychosocial interventions for English-speaking adults with  
24 heterogeneous cancer diagnoses. *Supportive care in cancer : official journal of the*  
25 *Multinational Association of Supportive Care in Cancer* 2010;18(10):1241-62.
- 26 55. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Lo SK, et al. The development and  
27 evaluation of a measure to assess cancer survivors' unmet supportive care needs: the CaSUN  
28 (Cancer Survivors' Unmet Needs measure). *Psychooncology* 2007;16(9):796-804.
- 29 56. Schofield P, Gough K, Lotfi-Jam K, Aranda S. Validation of the Supportive Care Needs Survey—  
30 short form 34 with a simplified response format in men with prostate cancer. *Psycho-*  
31 *Oncology* 2012;21(10):1107-12.
- 32 57. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the  
33 expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-  
34 related quality of life in men with prostate cancer. *Urology* 2000;56(6):899-905.
- 35 58. Marshall G, Hays R. The patient satisfaction questionnaire short-form (PSQ-18): RAND  
36 Corporation, 1994.
- 37 59. Ware JE, Jr., Davies-Avery A, Stewart AL. The measurement and meaning of patient satisfaction.  
38 *Health Med Care Serv Rev* 1978;1(1):1, 3-15.
- 39 60. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the  
40 remarkable universality of half a standard deviation. *Medical care* 2003;41(5):582-92.
- 41 61. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. *Oncology*  
42 2001;15(8):1049-59; discussion 60-2, 64-5, 69-70,73-5.
- 43 62. Watson EK, Rose P, Neal RD, Hulbert-Williams N, Donnelly P, Hubbard G, et al. Personalised  
44 cancer follow-up: risk stratification, needs assessment or both? *British journal of cancer*  
45 2012;106:1-5.
- 46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1a. Frequency of follow up visits in control and intervention arms  
(surgery and radiotherapy, and radiotherapy only)

Time since treatment completion							
	Recruitment to study (Baseline) Up to 3 weeks after end of treatment	2 weeks after randomisation	6 weeks	3 months	6 months	9 months	12 months
<b>Usual care</b> CONTROL arm			Hospital	Hospital	Hospital	Hospital	Hospital
<b>Shared care</b> INTERVENTION arm		GP	Hospital	Hospital	GP	GP	Hospital
Completion of questionnaires	✓ <sup>†</sup>			✓	✓		✓
PSA testing and examination				✓	✓	✓	✓


† Baseline questionnaire completed prior to randomisation

Table 1b. Frequency of follow up visits in control and intervention arms  
(surgery only)

Time since treatment completion						
	Recruitment to study (Baseline) Up to 8 weeks post-surgery	2 weeks after randomisation	3 months	6 months	9 months	12 months
<b>Usual care</b> CONTROL arm			Hospital	Hospital	Hospital	Hospital
<b>Shared care</b> INTERVENTION arm		GP	Hospital	GP	GP	Hospital
Completion of questionnaires	✓ <sup>†</sup>		✓	✓		✓
PSA testing and examination			✓	✓	✓	✓

† Baseline questionnaire completed prior to randomisation

Figure 1. Trial Flowchart



BMJ Open: first published as 10.1136/bmjopen-2014-004972 on 6 March 2014. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.



**Protocol for the ProCare Trial: a Phase II randomised controlled trial of shared care for follow-up of men with prostate cancer.**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004972.R1
Article Type:	Protocol
Date Submitted by the Author:	10-Feb-2014
Complete List of Authors:	Emery, Jon; University of Melbourne, General Practice and Primary Care Academic Centre Doorey, Juanita; University of Western Australia, School of Primary, Aboriginal and Rural Health Care Jefford, Michael; Peter MacCallum Cancer Centre, Medical Oncology King, Madeleine; University of Sydney, PsychoOncology Cooperative Research Group (PoCoG) Pirootta, Marie; University of Melbourne, General Practice and Primary Care Academic Centre Hayne, Dickon; Fremantle Hospital, Urology Department Martin, Andrew; University of Sydney, 7. NHMRC Clinical Trials Centre Trevena, Lyndal; University of Sydney, School of Public Health Lim, Tee; Royal Perth Hospital, Genesis Cancer Care Constable, Roger; Prostate Cancer Foundation of Australia, Hawks, Cynthia; Fremantle Hospital, Urology Department Hyatt, Amelia; Peter MacCallum Cancer Centre, Medical Oncology Hamid, Akhil; Royal Perth Hospital, Urology Department Violet, John; Peter MacCallum Cancer Centre, Radiation Oncology Department Gill, Suki; Peter MacCallum Cancer Centre, Radiation Oncology Department Frydenberg, Mark; Monash University, Department of Surgery Schofield, Penelope; Peter MacCallum Cancer Centre, Department of Cancer Experiences Research
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	General practice / Family practice, Health services research, Urology
Keywords:	Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Urological tumours < ONCOLOGY, PRIMARY CARE, Prostate disease < UROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Protocol for the ProCare Trial: a Phase II randomised controlled trial of shared care for follow-up**  
4 **of men with prostate cancer.**  
5  
6

7 **Authors:** Jon Emery <sup>1,2</sup>, Juanita Doorey <sup>2</sup>, Michael Jefford <sup>3</sup>, Madeleine King <sup>4</sup>, Marie Pirota <sup>1</sup>, Dickon  
8 Hayne <sup>5,6</sup>, Andrew Martin <sup>7</sup>, Lyndal Trevena <sup>8</sup>, Tee Lim <sup>9</sup>, Roger Constable <sup>10</sup>, Cynthia Hawks <sup>6</sup>, Amelia  
9 Hyatt <sup>11</sup>, Akhlil Hamid <sup>12</sup>, John Violet <sup>13</sup>, Suki Gill <sup>13</sup>, Mark Frydenberg <sup>14</sup>, Penelope Schofield <sup>11</sup>.  
10  
11

12  
13 **Author affiliations**  
14

- 15 1. General Practice and Primary Health Care Academic Centre, The University of Melbourne
- 16 2. General Practice, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia
- 17 3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria
- 18 4. Psycho-oncology Co-operative Research Group (PoCoG), School of Psychology, The University of Sydney
- 19 5. School of Surgery, The University of Western Australia
- 20 6. Urology Department, Fremantle Hospital, Western Australia
- 21 7. NHMRC Clinical Trials Centre, Sydney Medical School, The University of Sydney
- 22 8. School of Public Health, The University of Sydney
- 23 9. Genesis Cancer Care, Royal Perth Hospital, Western Australia
- 24 10. Prostate Cancer Foundation of Australia
- 25 11. Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria
- 26 12. Urology Department, Royal Perth Hospital, Western Australia
- 27 13. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria
- 28 14. Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University

29  
30  
31  
32  
33  
34  
35  
36 Corresponding author: [jon.emery@unimelb.edu.au](mailto:jon.emery@unimelb.edu.au)  
37  
38  
39

40  
41 **Abstract:** 270  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### Introduction

Men with prostate cancer require long term follow-up to monitor disease progression and manage common adverse physical and psychosocial consequences of treatment. There is growing recognition of the potential role of primary care in cancer follow-up. This paper describes the protocol for a phase II multisite randomised controlled trial of a novel model of shared care for the follow-up of men after completing treatment for low-moderate risk prostate cancer.

### Methods and Analysis

The intervention is a shared care model of follow-up visits in the first 12 months after completing treatment for prostate cancer with the following specific components: a survivorship care plan, GP management guidelines, register and recall systems, screening for distress and unmet needs and patient information resources. Eligible men will have completed surgery and/or radiotherapy for low-moderate risk prostate cancer within the previous eight weeks and have a GP who consents to participate. Ninety men will be randomised to the intervention or current hospital follow-up care. Study outcome measures will be collected at baseline, 3, 6 and 12 months and include anxiety, depression, unmet needs, prostate cancer-specific quality of life and satisfaction with care. Clinical processes and health care resource usage will also be measured. The principal emphasis of the analysis will be on obtaining estimates of the treatment effect size and assessing feasibility in order to inform the design of a subsequent phase III trial.

### Ethics and Dissemination

Ethics approval has been granted by the University of Western Australia and from all hospital recruitment sites in Western Australia and Victoria. Results of this phase II trial will be reported in peer-reviewed publications and in conference presentations.

### Trial Registration

Australian New Zealand Clinical Trial Registry ACTRN12610000938000

### Strengths and limitations of study

- This is the first randomised controlled trial of a model of shared care for men with prostate cancer;
- It is also the first trial to use the Distress Thermometer in primary care and the first to test a specific checklist to identify unmet needs of cancer survivors in primary care.
- As a phase II trial of a complex intervention it is designed to provide preliminary estimates of the feasibility and the efficacy of the shared care intervention for phase III planning purposes

## Introduction

Prostate cancer is the second most common cause of cancer among men worldwide, with the highest estimated incidence rates being in Australia and New Zealand, North America and western and northern Europe.<sup>1</sup> Age-standardised incidence rates in 2008 per 100,000 males were 104.2 in Australia and New Zealand; 93.1 in Western Europe and 85.6 in Northern America.<sup>2</sup> In Australia 19,438 men were newly diagnosed with prostate cancer in 2009<sup>3</sup> and the incidence is projected to increase to approximately 25,310 by 2020.<sup>4</sup> In the United States, there were an estimated 246,000 new prostate cancer cases in 2010 and this is projected to rise to 322,000 by 2020.<sup>5</sup> These changes in prostate cancer incidence are largely due to the growing use of the PSA as a screening test but also due to the ageing population.<sup>3</sup>

Although prostate cancer is a common cause of death from cancer, 5-year survival is relatively high. Between 2006 and 2010, the 5-year relative survival rate for men diagnosed with prostate cancer in Australia was 92%, with survival being highest for men aged 50 – 69 years.<sup>3</sup> Most recent data from the United States show a 5-year relative survival for prostate cancer of 99%.<sup>6</sup> Men who have completed treatment for prostate cancer require long term follow-up, to detect recurrence or progression of the disease, monitor any adverse effects of treatment and to identify and address any ongoing psychosocial needs.<sup>7</sup> Men with prostate cancer also frequently have a range of comorbid conditions requiring management.

### *Prostate cancer: high burden of illness*

Observational studies from the USA and UK have demonstrated that men treated for prostate cancer frequently experience distressing and ongoing side-effects, most notably urinary and bowel incontinence, sexual dysfunction, and significant psychological issues.<sup>8,9</sup> The severity and duration of side effects vary by treatment modality. A recently published study from the United States of 1655 men treated for localised prostate cancer with 15 years follow-up found that men having a prostatectomy were more likely to have urinary incontinence and erectile dysfunction at 2 and 5 years post-treatment than those undergoing radiotherapy, but less likely to have bowel urgency.<sup>10</sup>

Research also demonstrates that following prostate cancer treatment the majority of men have unmet psychological and supportive care needs. A cross sectional survey of 1001 men with prostate cancer living in seven European countries found that 81% had some unmet supportive care needs, including psychological, sexual and health system and information needs.<sup>11</sup> In a population-based cohort of 978 Australian men with recently treated prostate cancer, 54% had unmet psychological needs, particularly 'uncertainty about the future' (21%) and 47% unmet sexual needs.<sup>12</sup> A larger Australian longitudinal study with three year follow-up compared men treated for prostate cancer with matched controls to account for potential effects of normal ageing. Men treated for prostate cancer had lower sexual function, especially those on androgen deprivation therapy (97% impotence at 3 years), compared with 53% under active surveillance.<sup>13</sup> At three years, 67.9% of men who had nerve sparing radical prostatectomy and 86.7% of men who had non-nerve sparing radical prostatectomy were impotent. Men treated with radical prostatectomy reported worst urinary function (16% incontinence at 1 year, 12% at 3 years) compared with 3% incontinence after 3 years in the active surveillance group; and bowel function was worst in those receiving external beam radiotherapy (15% moderate or severe bowel problems at 3 years; compared with 3% after 3 years of active surveillance.)

### *Current care of men with prostate cancer in general practice*

The role of general practitioners (GPs) in prostate cancer screening is well recognised. General practice is also heavily engaged in managing men with prostate cancer including long term treatment and related health problems. Longitudinal data from the United Kingdom on nearly 5000 prostate cancer survivors (5 years or longer post diagnosis) found that these men consulted their GP up to three more times annually compared to controls, a trend that continued even 15 years after diagnosis.<sup>14</sup> Compared to matched controls, prostate cancer survivors had 39% more consultations over a 3-year follow-up period, partly due to monitoring and administration of hormonal treatments. Data from the Netherlands also showed that prostate cancer patients consult their GP more than controls at 2–5 years after diagnosis, for both cancer-related health problems and chronic disease management.<sup>15</sup>

In Australia, data from the Bettering the Evaluation and Care of Health (BEACH) study showed that, of 2,385 general practice consultations about prostate cancer in 2008 only 9% were for prostate cancer as a new problem (personal communication).<sup>16</sup> The following services were provided: PSA test request (21%); counselling, advice and education (15%); local injection / implant insertion (12%); prescription, predominantly for opioids and anti-androgens (approximately 30%); and referral, predominantly to urology or oncology (10%).

An expanded role for primary care in the follow-up of people with cancer is increasingly seen as critical for long term sustainability of the health system in many developed nations.<sup>17 18</sup> This is recognised in UK's National Cancer Survivorship Initiative<sup>19</sup> and, specifically in relation to prostate cancer, by the National Institute for Health and Clinical Excellence.<sup>20</sup>

A systematic review of primary care based follow-up in trials with breast and colon cancer survivors found no statistically significant differences between primary and secondary care follow up in terms of patient wellbeing, psychological morbidity, and patient satisfaction.<sup>21</sup> A randomised controlled trial of GP-led follow-up of people with melanoma found no significant difference in health status or anxiety and depression between intervention and control groups. However, there were significant improvements in some aspects of patient satisfaction with care for those receiving GP-led melanoma follow-up.<sup>22</sup> A recent rapid review of the evidence reported on seven trials of shared care in cancer; most of these focused on increasing the primary care team's involvement in managing symptoms during or immediately following treatment for cancer.<sup>23 24</sup> These trials found that shared care models of cancer follow-up can improve a range of important process outcomes including patient and provider satisfaction, provider confidence and knowledge, and patient perceptions of care. No trials of shared care have tested a structured approach to sharing cancer surveillance, management of treatment-related effects and psychosocial support between hospital and primary care after completion of treatment. Furthermore, there are no trials reported to date of prostate cancer follow-up in primary care.

Previous trials of primary care follow-up have focused on detection of recurrence to the exclusion of the multiple needs and co-morbidities of patients which may be more appropriately dealt with from a generalist perspective.<sup>23 25</sup> The key elements in a conceptual model of generalism include accessibility, holistic patient-centred, team-based care, care coordination, continuity and management of complex multiple problems.<sup>26</sup> Evidence from previous studies with cancer survivors followed up in primary care suggest that they are more likely to receive preventive interventions for conditions other than cancer, whereas those followed up by oncologists are more likely to receive interventions directed at cancer surveillance.<sup>27</sup> Primary care may therefore have an important broader generalist role to play in cancer follow-up.



*Principles underpinning a novel shared care model of follow-up for prostate cancer*

In 2005, the US Institute of Medicine (IOM) released a landmark report *From Cancer Patient to Cancer Survivor: Lost in Transition*.<sup>28</sup> The report recommended that new research initiatives focused on cancer patient follow-up were urgently needed to guide effective survivorship care. The IOM report outlined four essential components of survivorship care planning:

(1) prevention of recurrent and new cancers, and of other late effects; (2) surveillance for cancer spread, recurrence, or second cancers; assessment of medical and *psychosocial* late effects; (3) interventions for consequences of cancer and its treatment; and (4) coordination between specialists and primary care providers to ensure that all of the survivor's health needs are addressed.

The most common systemic problems in providing comprehensive cancer care include requirement for a case manager, local accessible health services and doctors who communicate with each other.<sup>29</sup> A systematic review of guidelines for follow-up care in prostate cancer highlighted that most focus on the detection of cancer recurrence and assessment of the medical consequences of treatment, with little attention placed on identifying and responding to other key unmet needs.<sup>30</sup>

In the ProCare Trial we are applying the following principles to guide the design of a model of shared hospital and primary care for prostate cancer.

*a. Communication between hospital and primary care.*

A current major issue in cancer follow-up is coordination of care between specialists and general practice, partly due to out-dated approaches to communication. Timely and systematic communication between hospital and community care providers is urgently required to clarify the roles and responsibilities of all, including the person with cancer.<sup>31 32</sup> An Australian trial comparing methods of communication between hospital and general practices found that fax had higher receipt rates than post and was the most preferred method by GPs.<sup>33</sup> An innovative trial of electronic faxing of standardised information to GPs about a patient's chemotherapy regime has shown that this approach led to improved GP confidence in managing adverse effects of treatment and increased satisfaction with shared care.<sup>34</sup> Survivorship care plans (SCPs) are recommended as an important tool to facilitate communication and clarify responsibility during the transition from active treatment to survivorship.<sup>27</sup> There has only been one trial of the use of SCPs in primary care<sup>35</sup> but several methodological issues have been raised about this trial which may explain its negative findings<sup>36</sup> so further evidence is needed.

*b. Promotion of patient involvement and engagement.*

Cancer patients want to be involved with decision-making, and wish to participate in strategies to remain well.<sup>37</sup> Involving patients with chronic diseases in their disease management results in better communication with physicians, improved self-reported health and reduced health distress, few hospitalisations and reduced health costs.<sup>38 39</sup> Self-management approaches also have potential for ameliorating the functional and emotional problems experienced by prostate cancer survivors.<sup>40</sup> A systematic review of patient activation approaches has shown they can alter the content of consultations and improve the identification of patients' concerns.<sup>41</sup> Approaches that allow patients to list and share their concerns with their doctor, particularly if linked to practitioner interventions, showed particular promise in this review. A separate systematic review of problem checklists found that these can empower cancer patients to ask relevant questions in healthcare consultations.<sup>42</sup>

*c. Tailoring care to specific needs of individual patients.*

Cancer survivors have different needs.<sup>29 43</sup> Therefore, interventions need to be systematically tailored to each individual. A review of tailored versus standardised information interventions in the health promotion area found that tailored interventions were significantly more effective in promoting health behaviour outcomes.<sup>44</sup> A randomised controlled trial with 543 prostate and breast

1  
2  
3 cancer survivors tested the efficacy of sequentially tailored versus standardised materials on  
4 improving diet and exercise behaviours and found that those receiving tailored materials had  
5 improved lifestyle behaviours.<sup>45</sup>  
6

### 7 **Aims of the ProCare Trial**

8 The ProCare Trial is a phase II trial of a multifaceted intervention designed to: 1) be patient-centred  
9 by eliciting individual needs and assisting patients to direct their health care; 2) provide appropriate  
10 multidisciplinary referrals and tailored information to patients; 3) provide holistic care coordination  
11 by a GP to address the multifaceted physical, psychosexual and social needs of men with prostate  
12 cancer; and 4) improve the timeliness and content of communication between hospital and primary  
13 care.  
14

15  
16 The trial is set within the Medical Research Council framework for the development and evaluation  
17 of complex interventions.<sup>46 47</sup> The objectives of this phase II trial reflect the need to optimise the  
18 intervention, establish acceptability of the intervention and randomisation, confirm suitability of  
19 outcome measures and provide estimates of efficacy, and recruitment and attrition rates to allow  
20 planning of a larger phase III trial. It therefore does not specifically employ a statistical hypothesis-  
21 testing framework.  
22

### 23 **Methods and Analysis**

#### 24 *Trial design and randomisation*

25  
26 A phase I study that operationalised the different components of the intervention and explored  
27 clinical feasibility and acceptability has been completed. Eleven men who met the eligibility criteria  
28 were recruited from two hospitals in Perth, Western Australia, with all receiving the intervention  
29 and completing the outcome measures throughout the 12 months of follow-up. Participants were  
30 interviewed by telephone after each of their three GP visits, with the interview data demonstrating  
31 acceptability of the intervention. Issues pertaining to the intervention and the outcome measures  
32 have been addressed and incorporated into the Phase II trial.  
33

34  
35 The phase II trial is a multi-site randomised controlled trial. Men who meet the eligibility criteria and  
36 who consent to participate are randomised 1: 1 to either usual care (control arm) or to trial shared-  
37 care (intervention arm). Randomisation is being performed using a centralised independent tele-  
38 randomisation system managed by the NHMRC Clinical Trials Centre, based at the University of  
39 Sydney. Stratifying variables for randomisation are hospital site and treatment type.  
40

#### 41 *Population and setting*

42 Men are being recruited from one rural and three urban public treatment centres in two Australian  
43 states (Western Australia and Victoria); private patients are also being recruited from one centre in  
44 Victoria.  
45

#### 46 *Inclusion criteria*

- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
1. Pathologically confirmed prostate cancer.
  2. Completed surgery and / or radiotherapy (brachytherapy or external beam, and which may also include neo-adjuvant androgen deprivation therapy) with curative intent; study entry within 8 weeks post-operatively or 3 weeks after completion of radiotherapy.
  3. Able to read and write English at a level sufficient to give informed consent and complete study procedures including written questionnaires without an interpreter.
  4. Have a GP who agrees to participate in the trial.

### *Exclusion criteria*

1. Suspicion or evidence of metastatic disease.
2. Severe psychiatric or cognitive disorder, which in the opinion of the investigator would compromise participation the study.
3. Treatment with palliative intent.
4. No GP.
5. Patients with a pathologically confirmed diagnosis of prostate cancer with any of the following high risk features (cT3; Prostate Specific Antigen (PSA) >20 or Gleason score  $\geq$  8).
6. Patients having androgen deprivation therapy following radiotherapy, irrespective of risk level.

Minimal data will be completed with consent from eligible men who decline to participate to measure selection bias.

### *Participant and GP recruitment procedures*

Men receiving radiotherapy treatment are approached about the trial towards the end of their treatment, whilst men having surgery are approached once their histopathology results are confirmed. If men consent to participate, their GP is faxed trial information and a consent form. If their GP agrees to participate, the patient is formally enrolled in the trial and randomised. If the GP declines, the patient receives standard hospital follow-up care outside the trial. GPs are eligible to have more than one patient in the trial regardless of treatment allocation.

### *Intervention*

The intervention is based on a shared care model where two of the five routine hospital visits during the first 12 months of follow-up are replaced by GP visits. An additional GP visit shortly after the completion of their treatment for prostate cancer is intended to re-engage the patient with their GP (Table 1).

In addition to the altered schedule of follow-up, the following specific components of the intervention are designed to support the model of shared care:

1. Structured systematic communication, using a Survivorship Care Plan.
2. GP clinical management guidelines.
3. Register and recall system for follow-up appointments.
4. Screening for distress and unmet needs using the Distress Thermometer and Problem Checklist.<sup>48</sup>
5. Provision of patient information resources

### *Survivorship care plan*

A tailored survivorship care plan using information from the patient's hospital notes is developed at the end of treatment by a member of the research team. It is produced using an electronic template and includes information on: prostate cancer diagnosis and treatment history; treatment team and contact details for rapid access and advice; the schedule of follow-up visits and tests for recurrence; early and later side effects of treatment applicable to treatment modality; information on relevant local services and resources including the Cancer Council Helpline, prostate cancer support groups, and stress management and relaxation programs.

1  
2  
3 A draft of the care plan is discussed with the patient by telephone by one of the research team  
4 before their initial GP visit allowing additional information to be incorporated such as current  
5 adverse effects of treatment. The finalised care plan is provided to the patient, their GP and  
6 hospital specialist. The care plan is faxed to the GP before the first follow-up visit and is designed to  
7 be incorporated into the patient's GP medical record.  
8

#### 9 *GP management guidelines*

10 GP management guidelines, based on international and local guidelines,<sup>49 50</sup> are included in the GP's  
11 copy of the care plan. They include guidelines on frequency of PSA testing and digital rectal  
12 examination to detect and manage recurrence, management of common physical and psychosexual  
13 adverse treatment effects, interpretation of the Distress Thermometer, and referral information to  
14 relevant services (e.g. sexual health and continence services).  
15  
16

#### 17 *Register and recall system*

18 This is a well-established component of good chronic disease management to reduce loss to follow-  
19 up and implement timely care.<sup>51</sup> A reminder letter is sent by the research team to the patient to  
20 attend each follow-up appointment, either at the hospital or general practice. Reminder letters are  
21 sent to GPs before the six and nine month visits.  
22  
23

#### 24 *Screening for distress and concerns*

25 The Distress Thermometer (DT) is a widely used validated screening tool for assessing psychological  
26 distress in people affected by cancer.<sup>48</sup> Men complete the Distress Thermometer on the day of each  
27 GP visit and GPs are advised to explore the meaning of distress and consider depression or anxiety in  
28 men with a cut-off score of four or greater. A modified problem checklist, specific to prostate  
29 cancer, has been incorporated into the DT, and covers physical and psychosocial issues. Men are  
30 asked to tick any problems they have experienced in the previous week, identifying the three most  
31 important. They give the checklist to their GP at the beginning of the consultation, to shape the  
32 content of the consultation and to facilitate discussion of specific unmet needs.  
33  
34

#### 35 *Patient information resources*

36 In addition to the information within the survivorship care plan, patients are offered the following  
37 prostate cancer specific information, according to their specific circumstances:  
38

39 Localised prostate cancer: a guide for men and their families (Cancer Council Australia 2010, 4<sup>th</sup>  
40 edition);

41 Continence and prostate: A guide for men undergoing prostate surgery; (Continence Foundation of  
42 Australia, 2008)

43 Treat ED: prostate edition. Understanding the impact of prostate cancer treatment on erectile  
44 function (Eli Lilly Australia)

45 Maintaining your well-being: Information on depression and anxiety for men with prostate cancer  
46 and their partners (beyond blue in association with Prostate Cancer Foundation of Australia).  
47  
48

#### 49 **Control group**

50 Men in the control group receive clinical care according to current hospital practice with frequency  
51 of visits as outlined in Table 1, consistent with current international guidelines.<sup>50</sup>  
52

#### 53 **Outcomes and measures**

54 As a phase II trial we have not determined a single primary outcome measure but instead are  
55 applying a battery of established instruments to measure the effects of the various components of  
56  
57  
58  
59  
60

1  
2  
3 this complex intervention.<sup>47</sup> This will inform decisions about outcome measures for a future phase  
4 III trial.

5  
6 *Demographics and clinical variables* include: age, postcode, marital status, education level and  
7 occupation, treatment type, diagnosis, stage of disease and patient reported co-morbidities.

8  
9 *Patient-reported outcome measures*

10  
11 *Psychological Distress: Hospital Anxiety and Depression Scale (HADS)*<sup>52</sup>. This 14-item scale has been  
12 widely used to measure distress in people with cancer; it has been extensively validated and shown  
13 to perform well in a wide range of populations (Cronbach  $\alpha = 0.82$ ; sensitivity and specificity 0.80).<sup>53</sup>  
14 A systematic review of measures of distress in cancer patients has concluded that the HADS  
15 performs better than other similar measures.<sup>54</sup>

16  
17  
18 *Survivors' unmet needs: Cancer Survivors' Unmet Needs measure (CaSUN)* This 35-item scale assesses  
19 unmet needs across information, patient care, psychosocial, physical and sexual domains.<sup>55</sup> The  
20 scale has good acceptability, internal consistency (Cronbach  $\alpha = 0.96$ ) and construct validity. Due to  
21 difficulties with the response format experienced by some participants in the phase I study, a  
22 simplified four-point response format is being used in this trial (no, low, moderate and high need).<sup>56</sup>

23  
24  
25 *Quality of Life: Expanded Prostate Cancer Index Composite (EPIC)* assesses prostate-specific quality of  
26 life (32 items with 4 subscales: urinary, bowel, sexual and hormonal function). It has greater  
27 coverage of key domains and sensitivity to treatment effects than previous prostate-specific quality  
28 of life measures.<sup>57</sup> It shows good test-retest reliability and internal consistency for all domain  
29 summary scores (each  $r > 0.80$  and Cronbach's  $\alpha > 0.82$ ).

30  
31  
32 *The Short-form Patient Satisfaction Questionnaire (PSQ-18)* consists of 18 items covering access,  
33 convenience, continuity, perceived communication between healthcare providers and technical  
34 competence).<sup>58</sup> It shows good internal consistency (each Cronbach's  $\alpha > 0.7$ ) and strong correlations  
35 with the original 50-item PSQIII.<sup>59</sup> After piloting in the phase I study, this scale has been modified to  
36 refer explicitly to the cancer follow-up care provided by hospital doctors and general practitioners  
37 during the previous 12 months.

38  
39  
40 *Preference for Follow-up Care (PFC)* Questions about preferences for future follow-up care have  
41 been adapted from the Cancer Survivors Follow-up Care Study (Adult Survivors Survey; personal  
42 communication A Girgis) A direct question about preference for specific type of follow-up care has  
43 also been included.

44  
45  
46 Participants complete the HADs, CaSUN and EPIC at four times points: prior to randomisation and  
47 then at 3, 6 and 12 months follow-up. Participants complete the PSQ-18 and PFC after their 12  
48 month follow-up appointment.

49  
50  
51 *Clinical process measures*

52 The following clinical information will be collected from GP medical records and Medicare Australia  
53 data, including both Medical Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS)  
54 data:

- 55  
56  
57 a. Recurrence rates and detection: use of PSA according to protocol<sup>50</sup> and time to detect  
58 recurrence.

- b. Mental health care: e.g. prescribing of antidepressants; referrals to clinical psychologists and use of specific Medicare Mental Health Care Plan items.
- c. Detection and management of psychosexual adverse effects: e.g. prescribing of phosphodiesterase type-5 inhibitors and referrals to sexual health services.
- d. Detection and management of other physical adverse effects of treatment: prescribing pre-specified drugs for urinary and bowel symptoms (e.g. oxybutynin, prazosin, loperamide, steroid enemas) and referrals to continence physiotherapy or urology.
- e. Management of co-morbidities will be determined by pathology data for common tests performed in the management of common chronic disease (e.g. vascular disease and diabetes) and will include, for example, lipids and HbA1c. This is to assess whether the model of shared care has an effect on the management of other co-morbidities.

*Health care resource usage:* data will be collected regarding hospitalisations, visits to healthcare professionals, investigations and medications, predominantly through Medicare Australia (MBS and PBS) and GP record audit. Unit costs obtained from a variety of sources (e.g. Australian refined diagnosis-related groups, MBS and PBS) will be applied to the resource usage data collected within the trial to estimate the incremental cost of the shared care model versus standard care from a health service perspective.

*Trial feasibility:* as a phase II trial we will obtain data on patient eligibility, recruitment and attrition rates, GP recruitment and attrition rates, and response rates to outcome measures to inform decisions and planning for a larger phase III trial.

#### *Sample size*

The study is designed to provide preliminary estimates of the feasibility and the efficacy of the shared care intervention for phase III planning purposes and does not employ a statistical hypothesis testing framework. The sample size is based on ensuring adequate information is collected to yield preliminary estimates of the treatment effect and of between-patient variation that are sufficiently precise for phase III trial planning purposes. The sample size target was revised at a steering committee meeting on 02 August 2012. This was in response to lower accrual rates than predicted, specifically due to a lower proportion of low-moderate risk prostate cancers than originally estimated. The revised target of 90 men was selected to ensure that the 95% confidence intervals for the mean difference between the two groups on the patient reported outcome measures would extend no further than +/- 0.5 of a standard deviation with 80% probability and allowing for 10% attrition at 12 months (i.e. complete data on N = 80 is required). This level of precision corresponds to what has been proposed as a minimal clinically important difference of health-related quality of life measures<sup>60</sup> allowing us to identify clinically significant harm from the intervention if it existed. Data from a trial of a group-based intervention involving 331 men with prostate cancer in Victoria, Australia ( ACTRN12606000184572) has been used to estimate how this level of precision will translate to estimates from the HADS and EPIC instruments.

Recruitment was completed in July 2013.

### Analyses

Baseline characteristics of the two arms will be described. Possible attrition bias will be assessed by comparing non-completion rates between treatment groups in conjunction with the baseline characteristics of those who withdraw or die against those who remain in the study.

*Estimating potential effect size and coefficient of variation:* Mean scores of HADS, CaSUN, EPIC and PSQ-18 will be compared between intervention and usual care groups. Mean differences between groups will be calculated with 95% confidence intervals at each follow-up time-point with and without adjusting for baseline score, site and treatment type (surgery and / or radiotherapy). Treatment groups will be compared on the categorical endpoints (e.g. clinical process measures) using chi-squared tests. Logistic regression modelling will also be undertaken to estimate the treatment effect on these endpoints adjusting for baseline covariates. The principal emphasis of the analysis will be on obtaining estimates of the treatment effect size and assessing feasibility in order to inform the design of a subsequent phase III trial. P-values for the multiple comparisons between the groups will be interpreted in this context.

### Discussion

The ProCare Trial has several novel elements: it is the first randomised controlled trial of a model of shared care for men with prostate cancer; it is the first trial to use the Distress Thermometer in primary care and the first to test a specific problem checklist to identify unmet needs of cancer survivors in primary care. We are testing a survivorship care plan (SCP) in primary care. One of the problems with the Grunfeld trial of SCPs in primary care was the high proportion of prevalent cancer cases who had completed treatment several years previously, and were possibly less likely to benefit.<sup>35 36</sup> We are therefore only recruiting men who have very recently completed their cancer treatment and in their first 12 months of follow-up care.

As a phase II trial it is designed to yield estimates of sufficient precision for phase III trial planning purposes. However, as with all trials of alternative models of cancer follow-up, an outstanding methodological issue is the selection of an appropriate primary outcome measure. Most trials have measured satisfaction with care and a range of health-related quality of life measures, finding no differences between hospital and primary care follow-up.<sup>23</sup> Trials in populations at low risk of cancer recurrence would need to be unfeasibly large to detect differences in survival. The ProCare Trial includes a range of outcome measures including disease-specific quality of life and unmet need. The intervention is designed to improve the identification of unmet needs and implement best practice management in the expectation that this will improve disease-specific quality of life and overall well-being.

We are recruiting men from a range of metropolitan and rural settings in two states in Australia including public and private healthcare settings. Based on discussions with urologists and radiation oncologists we have chosen only to recruit men with low-intermediate risk of disease recurrence, based on the D'Amico criteria.<sup>61</sup> As the first trial of shared follow-up care in prostate cancer it was agreed by the investigator team for safety reasons to focus initially on men with low-intermediate risk disease. This is also consistent with international approaches to risk stratified follow-up.<sup>62</sup> Our trial population is likely to be representative of a wide range of men with low-intermediate risk prostate cancer who might be offered alternative follow-up arrangements if this model of care were shown to be feasible and acceptable.

We plan to complete follow-up in July 2014 and report trial results in early 2015.

### Ethics

Ethics approval has been granted from the University of Western Australia's Human Research Ethics Committee (RA / 4/ 1/ 4447) as well as from all hospital recruitment sites in Western Australia and

1  
2  
3 Victoria. The study has also been approved by the External Review Committee of the  
4 Commonwealth Department of Human Services to obtain Medicare Benefits Schedule and  
5 Pharmaceutical Benefits Schedule data from participants with their consent.  
6

### 7 **Dissemination**

8 This is the first randomised controlled trial of a model of shared care for men with prostate cancer; it  
9 is also the first trial to use the Distress Thermometer in primary care and the first to test a specific  
10 checklist to identify unmet needs of cancer survivors in primary care. We plan to publish the main  
11 trial outcomes in a single paper and anticipate publishing additional papers exploring the data in  
12 more detail and relating to the implementation of this complex intervention. We will also present  
13 the findings at national and international conferences from late 2014.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Acknowledgements

This trial is supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

We thank the following people who have also been involved in the establishment and conduct of this trial: Sharon Ray, Sema Cakan, Anna Ugalde, Rose Kamateros, Emily Habgood, Danielle Miller and Shona Silvester.

We are grateful to all the trial participants, GPs and hospital specialists involved in the trial.

### Funding

This trial is supported by the National Health and Medical Research Council (grant ID 1003414). Associate Professor Schofield and Associate Professor Pirodda are supported by National Health and Medical Research Council Career Development Fellowships. The funder will have no role in the analysis or dissemination of results.

### Contributors

JE coordinated the design, funding award and implementation of the study and led the writing of the manuscript.

JD coordinated the recruitment and data collection for the study and contributed to the writing of the manuscript.

MJ contributed to the design, funding award and implementation of the study and to the writing of the manuscript.

MK contributed to the design, funding award and implementation of the study and to the writing of the manuscript.

MP contributed to the study design, funding award and implementation of the study and to the writing of the manuscript.

DH contributed to the study design, funding award and implementation of the study in WA and contributed to the writing of the manuscript.

AM contributed to the study design, funding award and statistical advice and contributed to the writing of the manuscript.

LT contributed to the design, funding award and implementation of the study and to the writing of the manuscript.

TL provided clinical expertise and was principal investigator at Royal Perth Hospital recruitment site; RC provided expertise from consumer perspective for study design, funding award and implementation of the study.

CH undertook recruitment and data collection at Fremantle Hospital, WA

AmH undertook recruitment and data collection for Victorian sites and approved the final manuscript.

AkH was principal investigator at Royal Perth Hospital Urology Services, WA and approved the final manuscript.

JV was principal investigator at Peter MacCallum Cancer Centre, Sunshine Hospital, Victoria and approved the final manuscript.

SG was principal investigator at Peter MacCallum Cancer Centre, Bendigo Hospital, Victoria and approved the final manuscript.

MF was principal investigator at Cabrini Hospital and Bairnsdale Hospital, Victoria and approved the final manuscript.

PS contributed to the study design, funding award and implementation of the study in Victoria and to the writing of the manuscript.

### Competing interests

None

### References

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *European urology* 2012;61(6):1079-92.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International journal of cancer. Journal international du cancer* 2010;127(12):2893-917.
3. Cancer in Australia: an overview. Canberra: Australian Institute of Health and Welfare, 2012.
4. Cancer incidence projections: Australia, 2011-2020. Canberra: Australian Institute of Health and Welfare, 2012.
5. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009;27(17):2758-65.
6. SEER Stat Fact Sheets: Prostate Cancer: National Cancer Institute, 2013.
7. O'Brien R, Rose PW, Campbell C, et al. Experiences of follow-up after treatment in patients with prostate cancer: a qualitative study. *BJU International* 2010;106(7):998-1003.
8. Boberg E, Gustafson D, Hawkins R, et al. Assessing the unmet information, support and care delivery needs of men with prostate cancer. *Patient Educ Counsel* 2003;49:233-42.
9. Ream E, Quennell A, Fincham L, et al. Supportive care needs of men living with prostate cancer in England: a survey. *British Journal of Cancer* 2008;98:1903-09.
10. Resnick MJ, Koyama T, Fan K-H, et al. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. *New England Journal of Medicine* 2013;368(5):436-45.
11. Cockle-Hearne J, Charnay-Sonnek F, Denis L, et al. The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. *British journal of cancer* 2013;109(8):2121-30.
12. Smith DP, Supramaniam R, King MT, et al. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer. *J Clin Oncol* 2007;25(18):2560-6.
13. Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. *BMJ* 2009;339:b4817.
14. Khan NF, Watson E, Rose PW. Primary care consultation behaviours of long-term, adult survivors of cancer in the UK. *British Journal of General Practice* 2011;61(584):197-99.
15. Heins MJ, Korevaar JC, Rijken PM, et al. For which health problems do cancer survivors visit their General Practitioner? *European journal of cancer* 2013;49(1):211-18.
16. The BEACH Project: Bettering the Evaluation and Care of Health Australian General Practice Statistics and Classification Centre, 2009.
17. Role Redesign Primary Care – Shared Care. Models of Cancer Treatment and Surveillance Post Treatment. Final Report. . In: Communications. GCa, editor. Canberra: Cancer Australia, 2010.
18. Pascoe SW, Neal RD, Allgar VL, et al. Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. *Fam Pract* 2004;21(4):437-42.
19. Richards M, Corner J, Maher J. The National Cancer Survivorship Initiative: new and emerging evidence on the ongoing needs of cancer survivors. *British journal of cancer* 2011;105 Suppl 1:S1-4.
20. Prostate cancer: diagnosis and treatment. London: National Institute of Clinical Excellence, 2008.
21. Lewis RA, Neal RD, Williams NH, et al. Follow-up of cancer in primary care versus secondary care: systematic review. *The British journal of general practice : the journal of the Royal College of General Practitioners* 2009;59(564):e234-47.
22. Murchie P, Nicolson MC, Hannaford PC, et al. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. *British journal of cancer* 2010;102(10):1447-55.

23. Emery JD, Trevena L, Mazza D, et al. The role of primary and community-based healthcare professionals in early detection and follow-up of cancer: a rapid review of best practice models. Sydney, NSW: Sax Institute, 2013.
24. Emery JD, Shaw K, Williams B, et al. The role of primary care in early detection and follow-up of cancer. *Nature reviews. Clinical oncology* 2014;11(1):38-48.
25. Taggart F, Donnelly P, Dunn J. Options for early breast cancer follow-up in primary and secondary care - a systematic review. *BMC cancer* 2012;12:238.
26. Gunn JM, Palmer VJ, Naccarella L, et al. The promise and pitfalls of generalism in achieving the Alma-Ata vision of health for all. *Med J Aust* 2008;189(2):110-2.
27. Grunfeld E, Earle C. The Interface Between Primary and Oncology Speciality Care: Treatment Through Survivorship. *J Natl Cancer Inst. Monographs* 2010(40):25-30.
28. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington DC, 2006.
29. Hodgkinson K, Butow P, Hobbs KM, et al. After cancer: the unmet supportive care needs of survivors and their partners. *J Psychosoc Oncol* 2007;25(4):89-104.
30. McIntosh HM, Neal RD, Rose P, et al. Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. *Br J Cancer* 2009;100(12):1852-60.
31. Jiwa M, Saunders CM, Thompson SC, et al. Timely cancer diagnosis and management as a chronic condition: opportunities for primary care. *Med J Aust* 2008;189(2):78-82.
32. Walsh J, Harrison JD, Young JM, et al. What are the current barriers to effective cancer care coordination? A qualitative study. *BMC Health Services Research* 2010;10.
33. Chen Y, Brennan N, Magrabi F. Is email an effective method for hospital discharge communication? A randomized controlled trial to examine delivery of computer-generated discharge summaries by email, fax, post and patient hand delivery. *Int J Med Inform.*
34. Jefford M, Baravelli C, Dudgeon P, et al. Tailored chemotherapy information faxed to general practitioners improves confidence in managing adverse effects and satisfaction with shared care: results from a randomized controlled trial. *J Clin Oncol* 2008;26(14):2272-7.
35. Grunfeld E, Julian J, Pond G, et al. Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. *Journal of Clinical Oncology* 2011;29(36):4755-62.
36. Jefford M, Schofield P, Emery J. Improving survivorship care. *Journal of Clinical Oncology* 2012;30(12):1391-92.
37. Brown RF, Butow PN, Sharrock MA, et al. Education and role modelling for clinical decisions with female cancer patients. *Health Expect* 2004;7(4):303-16.
38. Barlow J, Wright C, Sheasby J. Self-management approaches for people with chronic conditions: a review. *Patient Educ Counsel* 2002;48:177-87.
39. Deadman J, Leinster S, Owens R. Taking responsibility for cancer treatment. *Soc Sci Med* 2001;53:669-77.
40. Cockle-Hearne J, Faithfull S. Self-management for men surviving prostate cancer: a review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. *Psycho-oncology* 2010;19(9):909-22.
41. Griffin SJ, Kinmonth AL, Veltman MW, et al. Effect on health-related outcomes of interventions to alter the interaction between patients and practitioners: a systematic review of trials. *Ann Fam Med* 2004;2(6):595-608.
42. Dimoska A, Tattersall MH, Butow PN, et al. Can a "prompt list" empower cancer patients to ask relevant questions? *Cancer* 2008;113(2):225-37.
43. Jefford M, Karahalios A, Angle A. Understanding issues for cancer survivors: informing the development of a written information booklet. *Psychooncology* 2007;16 S273.
44. Ryan P, Lauver DR. The efficacy of tailored interventions. *J Nurs Scholarsh* 2002;34(4):331-7.

- 1
- 2
- 3 45. Demark-Wahnefried W, Clipp EC, Lipkus IM, et al. Main outcomes of the FRESH START trial: a
- 4 sequentially tailored, diet and exercise mailed print intervention among breast and prostate
- 5 cancer survivors. *Journal of clinical oncology : official journal of the American Society of*
- 6 *Clinical Oncology* 2007;25(19):2709-18.
- 7
- 8 46. Developing and evaluating complex interventions: new guidance. London: Medical Research
- 9 Council., 2008.
- 10 47. Campbell N, Murray E, Darbyshire J, et al. Designing and evaluating complex interventions to
- 11 improve healthcare. *BMJ* 2007;334:455-59.
- 12 48. Jacobsen P, Donovan K, Trask P. Screening for psychologic distress in ambulatory care patients.
- 13 *Cancer* 2005;103:1494-502.
- 14 49. Localised prostate cancer: a guide for men and their families. : Andrology Australia & Australian
- 15 Prostate Cancer Collaboration. , 2009.
- 16 50. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer: European Association of
- 17 Urology, 2009.
- 18 51. Wagner EH, Austin BT, Davis C, et al. Improving Chronic Illness Care: Translating Evidence Into
- 19 Action. *Health Affairs* 2001;20:64-78.
- 20 52. Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*
- 21 1983;67:361-70.
- 22 53. Bjellanda I, Dahlb A, Haugc T, et al. The validity of the Hospital Anxiety and Depression Scale. An
- 23 updated literature review. *Journal of Psychosomatic Research* 2002; 52:69- 77.
- 24 54. Lockett T, Butow PN, King MT, et al. A review and recommendations for optimal outcome
- 25 measures of anxiety, depression and general distress in studies evaluating psychosocial
- 26 interventions for English-speaking adults with heterogeneous cancer diagnoses. *Supportive*
- 27 *care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*
- 28 2010;18(10):1241-62.
- 29 55. Hodgkinson K, Butow P, Hunt GE, et al. The development and evaluation of a measure to assess
- 30 cancer survivors' unmet supportive care needs: the CaSUN (Cancer Survivors' Unmet Needs
- 31 measure). *Psychooncology* 2007;16(9):796-804.
- 32 56. Schofield P, Gough K, Lotfi-Jam K, et al. Validation of the Supportive Care Needs Survey—short
- 33 form 34 with a simplified response format in men with prostate cancer. *Psycho-Oncology*
- 34 2012;21(10):1107-12.
- 35 57. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer
- 36 index composite (EPIC) for comprehensive assessment of health-related quality of life in
- 37 men with prostate cancer. *Urology* 2000;56(6):899-905.
- 38 58. Marshall G, Hays R. The patient satisfaction questionnaire short-form (PSQ-18): RAND
- 39 Corporation, 1994.
- 40 59. Ware JE, Jr., Davies-Avery A, Stewart AL. The measurement and meaning of patient satisfaction.
- 41 *Health Med Care Serv Rev* 1978;1(1):1, 3-15.
- 42 60. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the
- 43 remarkable universality of half a standard deviation. *Medical care* 2003;41(5):582-92.
- 44 61. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. *Oncology*
- 45 2001;15(8):1049-59; discussion 60-2, 64-5, 69-70,73-5.
- 46 62. Watson EK, Rose P, Neal RD, et al. Personalised cancer follow-up: risk stratification, needs
- 47 assessment or both? *British journal of cancer* 2012;106:1-5.
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1a. Frequency of follow up visits in control and intervention arms  
(surgery and radiotherapy, and radiotherapy only)

Time since treatment completion							
	Recruitment to study (Baseline) Up to 3 weeks after end of treatment	2 weeks after randomisation	6 weeks	3 months	6 months	9 months	12 months
<b>Usual care</b> CONTROL arm			Hospital	Hospital	Hospital	Hospital	Hospital
<b>Shared care</b> INTERVENTION arm		GP	Hospital	Hospital	GP	GP	Hospital
Completion of questionnaires	✓ <sup>†</sup>			✓	✓		✓
PSA testing and examination				✓	✓	✓	✓

† Baseline questionnaire completed prior to randomisation

Table 1b. Frequency of follow up visits in control and intervention arms  
(surgery only)

Time since treatment completion						
	Recruitment to study (Baseline) Up to 8 weeks post-surgery	2 weeks after randomisation	3 months	6 months	9 months	12 months
<b>Usual care</b> CONTROL arm			Hospital	Hospital	Hospital	Hospital
<b>Shared care</b> INTERVENTION arm		GP	Hospital	GP	GP	Hospital
Completion of questionnaires	✓ <sup>†</sup>		✓	✓		✓
PSA testing and examination			✓	✓	✓	✓

† Baseline questionnaire completed prior to randomisation

Figure 1. Trial Flowchart

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **Protocol for the ProCare Trial: a Phase II randomised controlled trial of shared care for follow-up**  
8 **of men with prostate cancer.**

9 **Authors:** Jon Emery <sup>1,2</sup>, Juanita Doorey <sup>2</sup>, Michael Jefford <sup>3</sup>, Madeleine King <sup>4</sup>, Marie Pirota <sup>1</sup>, Dickon  
10 Hayne <sup>5,6</sup>, Andrew Martin <sup>7</sup>, Lyndal Trevena <sup>8</sup>, Tee Lim <sup>9</sup>, Roger Constable <sup>10</sup>, Cynthia Hawks <sup>6</sup>, Amelia  
11 Hyatt <sup>11</sup>, Akhlil Hamid <sup>12</sup>, John Violet <sup>13</sup>, Suki Gill <sup>13</sup>, Mark Frydenberg <sup>14</sup>, Penelope Schofield <sup>11</sup>.

12  
13  
14 Corresponding author: [jon.emery@unimelb.edu.au](mailto:jon.emery@unimelb.edu.au)

15  
16 **Abstract**

17  
18 **Introduction**

19 Men with prostate cancer require long term follow-up to monitor disease progression and manage  
20 common adverse physical and psychosocial consequences of treatment. There is growing  
21 recognition of the potential role of primary care in cancer follow-up. This paper describes the  
22 protocol for a phase II multisite randomised controlled trial of a novel model of shared care for the  
23 follow-up of men after completing treatment for low-moderate risk prostate cancer.

24  
25 **Methods and Analysis**

26 The intervention is a shared care model of follow-up visits in the first 12 months after completing  
27 treatment for prostate cancer with the following specific components: a survivorship care plan, GP  
28 management guidelines, register and recall systems, screening for distress and unmet needs and  
29 patient information resources. Eligible men will have completed surgery and/or radiotherapy for  
30 low-moderate risk prostate cancer within the previous eight weeks and have a GP who consents to  
31 participate. Ninety men will be randomised to the intervention or current hospital follow-up care.  
32 Study outcome measures will be collected at baseline, 3, 6 and 12 months and include anxiety,  
33 depression, unmet needs, prostate cancer-specific quality of life and satisfaction with care. Clinical  
34 processes and health care resource usage will also be measured. The principal emphasis of the  
35 analysis will be on obtaining estimates of the treatment effect size and assessing feasibility in order  
36 to inform the design of a subsequent phase III trial.

37  
38 **Ethics and Dissemination**

39 Ethics approval has been granted by the University of Western Australia and from all hospital  
40 recruitment sites in Western Australia and Victoria. Results of this phase II trial will be reported in  
41 peer-reviewed publications and in conference presentations.

42  
43 **Trial Registration**

44 Australian New Zealand Clinical Trial Registry ACTRN12610000938000  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

### Strengths and limitations of study

- This is the first randomised controlled trial of a model of shared care for men with prostate cancer;
- It is also the first trial to use the Distress Thermometer in primary care and the first to test a specific checklist to identify unmet needs of cancer survivors in primary care.
- As a phase II trial of a complex intervention it is designed to provide preliminary estimates of the feasibility and the efficacy of the shared care intervention for phase III planning purposes

### Introduction

Prostate cancer is the second most common cause of cancer among men worldwide, with the highest estimated incidence rates being in Australia and New Zealand, North America and western and northern Europe.<sup>1</sup> Age-standardised incidence rates in 2008 per 100,000 males were 104.2 in Australia and New Zealand; 93.1 in Western Europe and 85.6 in Northern America.<sup>2</sup> In Australia 19,438 men were newly diagnosed with prostate cancer in 2009<sup>3</sup> and the incidence is projected to increase to approximately 25,310 by 2020.<sup>4</sup> In the United States, there were an estimated 246,000 new prostate cancer cases in 2010 and this is projected to rise to 322,000 by 2020.<sup>5</sup> These changes in prostate cancer incidence are largely due to the growing use of the PSA as a screening test but also due to the ageing population.<sup>3</sup>

Although prostate cancer is a common cause of death from cancer, 5-year survival is relatively high. Between 2006 and 2010, the 5-year relative survival rate for men diagnosed with prostate cancer in Australia was 92%, with survival being highest for men aged 50 – 69 years.<sup>3</sup> Most recent data from the United States show a 5-year relative survival for prostate cancer of 99%.<sup>6</sup> Men who have completed treatment for prostate cancer require long term follow-up, to detect recurrence or progression of the disease, monitor any adverse effects of treatment and to identify and address any ongoing psychosocial needs.<sup>7</sup> Men with prostate cancer also frequently have a range of comorbid conditions requiring management.

#### *Prostate cancer: high burden of illness*

Observational studies from the USA and UK have demonstrated that men treated for prostate cancer frequently experience distressing and ongoing side-effects, most notably urinary and bowel incontinence, sexual dysfunction, and significant psychological issues.<sup>8,9</sup> The severity and duration of side effects vary by treatment modality. A recently published study from the United States of 1655 men treated for localised prostate cancer with 15 years follow-up found that men having a prostatectomy were more likely to have urinary incontinence and erectile dysfunction at 2 and 5 years post-treatment than those undergoing radiotherapy, but less likely to have bowel urgency.<sup>10</sup>

Research also demonstrates that following prostate cancer treatment the majority of men have unmet psychological and supportive care needs. A cross sectional survey of 1001 men with prostate cancer living in seven European countries found that 81% had some unmet supportive care needs, including psychological, sexual and health system and information needs.<sup>11</sup> In a population-based cohort of 978 Australian men with recently treated prostate cancer, 54% had unmet psychological needs, particularly 'uncertainty about the future' (21%) and 47% unmet sexual needs.<sup>12</sup> A larger



1  
2  
3  
4  
5  
6  
7 Australian longitudinal study with three year follow-up compared men treated for prostate cancer  
8 with matched controls to account for potential effects of normal ageing. Men treated for prostate  
9 cancer had lower sexual function, especially those on androgen deprivation therapy (97% impotence  
10 at 3 years) , compared with 53% under active surveillance.<sup>13</sup> At three years, 67.9% of men who had  
11 nerve sparing radical prostatectomy and 86.7% of men who had non-nerve sparing radical  
12 prostatectomy were impotent. Men treated with radical prostatectomy reported worst urinary  
13 function (16% incontinence at 1 year, 12% at 3 years) compared with 3% incontinence after 3 years  
14 in the active surveillance group; and bowel function was worst in those receiving external beam  
15 radiotherapy (15% moderate or severe bowel problems at 3 years; compared with 3% after 3 years  
16 of active surveillance.)

### 17 *Current care of men with prostate cancer in general practice*

18 The role of general practitioners (GPs) in prostate cancer screening is well recognised. General  
19 practice is also heavily engaged in managing men with prostate cancer including long term  
20 treatment and related health problems. Longitudinal data from the United Kingdom on nearly 5000  
21 prostate cancer survivors (5 years or longer post diagnosis) found that these men consulted their GP  
22 up to three more times annually compared to controls, a trend that continued even 15 years after  
23 diagnosis.<sup>14</sup> Compared to matched controls, prostate cancer survivors had 39% more consultations  
24 over a 3-year follow-up period, partly due to monitoring and administration of hormonal treatments.  
25 Data from the Netherlands also showed that prostate cancer patients consult their GP more than  
26 controls at 2–5 years after diagnosis, for both cancer-related health problems and chronic disease  
27 management.<sup>15</sup>

28 In Australia, data from the Bettering the Evaluation and Care of Health (BEACH) study showed that,  
29 of 2,385 general practice consultations about prostate cancer in 2008 only 9% were for prostate  
30 cancer as a new problem(personal communication).<sup>16</sup> The following services were provided: PSA test  
31 request (21%); counselling, advice and education (15%); local injection / implant insertion (12%);  
32 prescription, predominantly for opioids and anti-androgens (approximately 30%); and referral,  
33 predominantly to urology or oncology (10%).

34 An expanded role for primary care in the follow-up of people with cancer is increasingly seen as  
35 critical for long term sustainability of the health system in many developed nations.<sup>17 18</sup> This is  
36 recognised in UK's National Cancer Survivorship Initiative<sup>19</sup> and, specifically in relation to prostate  
37 cancer, by the National Institute for Health and Clinical Excellence.<sup>20</sup>

38 A systematic review of primary care based follow-up in trials with breast and colon cancer survivors  
39 found no statistically significant differences between primary and secondary care follow up in terms  
40 of patient wellbeing, psychological morbidity, and patient satisfaction.<sup>21</sup> A randomised controlled  
41 trial of GP-led follow-up of people with melanoma found no significant difference in health status or  
42 anxiety and depression between intervention and control groups. However, there were significant  
43 improvements in some aspects of patient satisfaction with care for those receiving GP-led melanoma  
44 follow-up.<sup>22</sup> A recent rapid review of the evidence reported on seven trials of shared care in cancer;  
45 most of these focused on increasing the primary care team's involvement in managing symptoms  
46 during or immediately following treatment for cancer.<sup>23 24</sup> These trials found that shared care  
47 models of cancer follow-up can improve a range of important process outcomes including patient  
48 and provider satisfaction, provider confidence and knowledge, and patient perceptions of care. No  
49 trials of shared care have tested a structured approach to sharing cancer surveillance, management  
50 of treatment-related effects and psychosocial support between hospital and primary care after  
51 completion of treatment. Furthermore, there are no trials reported to date of prostate cancer  
52 follow-up in primary care.  
53  
54

1  
2  
3  
4  
5  
6  
7  
8 Previous trials of primary care follow-up have focused on detection of recurrence to the exclusion of  
9 the multiple needs and co-morbidities of patients which may be more appropriately dealt with from  
10 a generalist perspective.<sup>23 25</sup> The key elements in a conceptual model of generalism include  
11 accessibility, holistic patient-centred, team-based care, care coordination, continuity and  
12 management of complex multiple problems.<sup>26</sup> Evidence from previous studies with cancer survivors  
13 followed up in primary care suggest that they are more likely to receive preventive interventions for  
14 conditions other than cancer, whereas those followed up by oncologists are more likely to receive  
15 interventions directed at cancer surveillance.<sup>27</sup> Primary care may therefore have an important  
16 broader generalist role to play in cancer follow-up.

### 17 *Principles underpinning a novel shared care model of follow-up for prostate cancer*

18 In 2005, the US Institute of Medicine (IOM) released a landmark report From Cancer Patient to  
19 Cancer Survivor: Lost in Transition.<sup>28</sup> The report recommended that new research initiatives focused  
20 on cancer patient follow-up were urgently needed to guide effective survivorship care. The IOM  
21 report outlined four essential components of survivorship care planning:

22 (1) prevention of recurrent and new cancers, and of other late effects; (2) surveillance for cancer  
23 spread, recurrence, or second cancers; assessment of medical and *psychosocial* late effects; (3)  
24 interventions for consequences of cancer and its treatment; and (4) coordination between  
25 specialists and primary care providers to ensure that all of the survivor's health needs are addressed.

26 The most common systemic problems in providing comprehensive cancer care include requirement  
27 for a case manager, local accessible health services and doctors who communicate with each  
28 other.<sup>29</sup> A systematic review of guidelines for follow-up care in prostate cancer highlighted that  
29 most focus on the detection of cancer recurrence and assessment of the medical consequences of  
30 treatment, with little attention placed on identifying and responding to other key unmet needs.<sup>30</sup>

31 In the ProCare Trial we are applying the following principles to guide the design of a model of shared  
32 hospital and primary care for prostate cancer.

#### 33 *a. Communication between hospital and primary care.*

34 A current major issue in cancer follow-up is coordination of care between specialists and general  
35 practice, partly due to out-dated approaches to communication. Timely and systematic  
36 communication between hospital and community care providers is urgently required to clarify the  
37 roles and responsibilities of all, including the person with cancer.<sup>31 32</sup> An Australian trial comparing  
38 methods of communication between hospital and general practices found that fax had higher  
39 receipt rates than post and was the most preferred method by GPs.<sup>33</sup> An innovative trial of  
40 electronic faxing of standardised information to GPs about a patient's chemotherapy regime has  
41 shown that this approach led to improved GP confidence in managing adverse effects of treatment  
42 and increased satisfaction with shared care.<sup>34</sup> Survivorship care plans (SCPs) are recommended as  
43 an important tool to facilitate communication and clarify responsibility during the transition from  
44 active treatment to survivorship.<sup>27</sup> There has only been one trial of the use of SCPs in primary care<sup>35</sup>  
45 but several methodological issues have been raised about this trial which may explain its negative  
46 findings<sup>36</sup> so further evidence is needed.

#### 47 *b. Promotion of patient involvement and engagement.*

48 Cancer patients want to be involved with decision-making, and wish to participate in strategies to  
49 remain well.<sup>37</sup> Involving patients with chronic diseases in their disease management results in better  
50 communication with physicians, improved self-reported health and reduced health distress, few  
51 hospitalisations and reduced health costs.<sup>38 39</sup> Self-management approaches also have potential for  
52 ameliorating the functional and emotional problems experienced by prostate cancer survivors.<sup>40</sup> A  
53  
54

1  
2  
3  
4  
5  
6  
7 systematic review of patient activation approaches has shown they can alter the content of  
8 consultations and improve the identification of patients' concerns.<sup>41</sup> Approaches that allow patients  
9 to list and share their concerns with their doctor, particularly if linked to practitioner interventions,  
10 showed particular promise in this review. A separate systematic review of problem checklists found  
11 that these can empower cancer patients to ask relevant questions in healthcare consultations.<sup>42</sup>

12 *c. Tailoring care to specific needs of individual patients.*

13 Cancer survivors have different needs.<sup>29 43</sup> Therefore, interventions need to be systematically  
14 tailored to each individual. A review of tailored versus standardised information interventions in the  
15 health promotion area found that tailored interventions were significantly more effective in  
16 promoting health behaviour outcomes.<sup>44</sup> A randomised controlled trial with 543 prostate and breast  
17 cancer survivors tested the efficacy of sequentially tailored versus standardised materials on  
18 improving diet and exercise behaviours and found that those receiving tailored materials had  
19 improved lifestyle behaviours.<sup>45</sup>

20  
21 **Aims of the ProCare Trial**

22 The ProCare Trial is a phase II trial of a multifaceted intervention designed to: 1) be patient-centred  
23 by eliciting individual needs and assisting patients to direct their health care; 2) provide appropriate  
24 multidisciplinary referrals and tailored information to patients; 3) provide holistic care coordination  
25 by a GP to address the multifaceted physical, psychosexual and social needs of men with prostate  
26 cancer; and 4) improve the timeliness and content of communication between hospital and primary  
27 care.

28 The trial is set within the Medical Research Council framework for the development and evaluation  
29 of complex interventions.<sup>46 47</sup> The objectives of this phase II trial reflect the need to optimise the  
30 intervention, establish acceptability of the intervention and randomisation, confirm suitability of  
31 outcome measures and provide estimates of efficacy, and recruitment and attrition rates to allow  
32 planning of a larger phase III trial. It therefore does not specifically employ a statistical hypothesis-  
33 testing framework.

34  
35 **Methods and Analysis**

36 *Trial design and randomisation*

37 A phase I study that operationalised the different components of the intervention and explored  
38 clinical feasibility and acceptability has been completed. Eleven men who met the eligibility criteria  
39 were recruited from two hospitals in Perth, Western Australia, with all receiving the intervention  
40 and completing the outcome measures throughout the 12 months of follow-up. Participants were  
41 interviewed by telephone after each of their three GP visits, with the interview data demonstrating  
42 acceptability of the intervention. Issues pertaining to the intervention and the outcome measures  
43 have been addressed and incorporated into the Phase II trial.

44  
45 The phase II trial is a multi-site randomised controlled trial. Men who meet the eligibility criteria and  
46 who consent to participate are randomised 1: 1 to either usual care (control arm) or to trial shared-  
47 care (intervention arm). Randomisation is being performed using a centralised independent tele-  
48 randomisation system managed by the NHMRC Clinical Trials Centre, based at the University of  
49 Sydney. Stratifying variables for randomisation are hospital site and treatment type.

50  
51 *Population and setting*

52 Men are being recruited from one rural and three urban public treatment centres in two Australian  
53 states (Western Australia and Victoria); private patients are also being recruited from one centre in  
54 Victoria.

### *Inclusion criteria*

1. Pathologically confirmed prostate cancer.
2. Completed surgery and / or radiotherapy (brachytherapy or external beam, and which may also include neo-adjuvant androgen deprivation therapy) with curative intent; study entry within 8 weeks post-operatively or 3 weeks after completion of radiotherapy.
3. Able to read and write English at a level sufficient to give informed consent and complete study procedures including written questionnaires without an interpreter.
4. Have a GP who agrees to participate in the trial.

### *Exclusion criteria*

1. Suspicion or evidence of metastatic disease.
2. Severe psychiatric or cognitive disorder, which in the opinion of the investigator would compromise participation the study.
3. Treatment with palliative intent.
4. No GP.
5. Patients with a pathologically confirmed diagnosis of prostate cancer with any of the following high risk features (cT3; Prostate Specific Antigen (PSA) >20 or Gleason score  $\geq$  8).
6. Patients having androgen deprivation therapy following radiotherapy, irrespective of risk level.

Minimal data will be completed with consent from eligible men who decline to participate to measure selection bias.

### *Participant and GP recruitment procedures*

Men receiving radiotherapy treatment are approached about the trial towards the end of their treatment, whilst men having surgery are approached once their histopathology results are confirmed. If men consent to participate, their GP is faxed trial information and a consent form. If their GP agrees to participate, the patient is formally enrolled in the trial and randomised. If the GP declines, the patient receives standard hospital follow-up care outside the trial. GPs are eligible to have more than one patient in the trial regardless of treatment allocation.

### *Intervention*

The intervention is based on a shared care model where two of the five routine hospital visits during the first 12 months of follow-up are replaced by GP visits. An additional GP visit shortly after the completion of their treatment for prostate cancer is intended to re-engage the patient with their GP (Table 1).

In addition to the altered schedule of follow-up, the following specific components of the intervention are designed to support the model of shared care:

1. Structured systematic communication, using a Survivorship Care Plan.
2. GP clinical management guidelines.
3. Register and recall system for follow-up appointments.
4. Screening for distress and unmet needs using the Distress Thermometer and Problem Checklist.<sup>48</sup>

5. Provision of patient information resources

*Survivorship care plan*

A tailored survivorship care plan using information from the patient's hospital notes is developed at the end of treatment by a member of the research team. It is produced using an electronic template and includes information on: prostate cancer diagnosis and treatment history; treatment team and contact details for rapid access and advice; the schedule of follow-up visits and tests for recurrence; early and later side effects of treatment applicable to treatment modality; information on relevant local services and resources including the Cancer Council Helpline, prostate cancer support groups, and stress management and relaxation programs.

A draft of the care plan is discussed with the patient by telephone by one of the research team before their initial GP visit allowing additional information to be incorporated such as current adverse effects of treatment. The finalised care plan is provided to the patient, their GP and hospital specialist. The care plan is faxed to the GP before the first follow-up visit and is designed to be incorporated into the patient's GP medical record.

*GP management guidelines*

GP management guidelines, based on international and local guidelines,<sup>49 50</sup> are included in the GP's copy of the care plan. They include guidelines on frequency of PSA testing and digital rectal examination to detect and manage recurrence, management of common physical and psychosexual adverse treatment effects, interpretation of the Distress Thermometer, and referral information to relevant services (e.g. sexual health and continence services).

*Register and recall system*

This is a well-established component of good chronic disease management to reduce loss to follow-up and implement timely care.<sup>51</sup> A reminder letter is sent by the research team to the patient to attend each follow-up appointment, either at the hospital or general practice. Reminder letters are sent to GPs before the six and nine month visits.

*Screening for distress and concerns*

The Distress Thermometer (DT) is a widely used validated screening tool for assessing psychological distress in people affected by cancer.<sup>48</sup> Men complete the Distress Thermometer on the day of each GP visit and GPs are advised to explore the meaning of distress and consider depression or anxiety in men with a cut-off score of four or greater. A modified problem checklist, specific to prostate cancer, has been incorporated into the DT, and covers physical and psychosocial issues. Men are asked to tick any problems they have experienced in the previous week, identifying the three most important. They give the checklist to their GP at the beginning of the consultation, to shape the content of the consultation and to facilitate discussion of specific unmet needs.

*Patient information resources*

In addition to the information within the survivorship care plan, patients are offered the following prostate cancer specific information, according to their specific circumstances:

Localised prostate cancer: a guide for men and their families (Cancer Council Australia 2010, 4<sup>th</sup> edition);

Continence and prostate: A guide for men undergoing prostate surgery; (Continence Foundation of Australia, 2008)

Treat ED: prostate edition. Understanding the impact of prostate cancer treatment on erectile function (Eli Lilly Australia)

Maintaining your well-being: Information on depression and anxiety for men with prostate cancer and their partners (beyond blue in association with Prostate Cancer Foundation of Australia).

### Control group

Men in the control group receive clinical care according to current hospital practice with frequency of visits as outlined in Table 1, consistent with current international guidelines.<sup>50</sup>

### Outcomes and measures

As a phase II trial we have not determined a single primary outcome measure but instead are applying a battery of established instruments to measure the effects of the various components of this complex intervention.<sup>47</sup> This will inform decisions about outcome measures for a future phase III trial.

*Demographics and clinical variables* include: age, postcode, marital status, education level and occupation, treatment type, diagnosis, stage of disease and patient reported co-morbidities.

#### *Patient-reported outcome measures*

*Psychological Distress: Hospital Anxiety and Depression Scale (HADS)*<sup>52</sup>. This 14-item scale has been widely used to measure distress in people with cancer; it has been extensively validated and shown to perform well in a wide range of populations (Cronbach  $\alpha = 0.82$ ; sensitivity and specificity 0.80).<sup>53</sup> A systematic review of measures of distress in cancer patients has concluded that the HADS performs better than other similar measures.<sup>54</sup>

*Survivors' unmet needs: Cancer Survivors' Unmet Needs measure (CaSUN)* This 35-item scale assesses unmet needs across information, patient care, psychosocial, physical and sexual domains.<sup>55</sup> The scale has good acceptability, internal consistency (Cronbach  $\alpha = 0.96$ ) and construct validity. Due to difficulties with the response format experienced by some participants in the phase I study, a simplified four-point response format is being used in this trial (no, low, moderate and high need).<sup>56</sup>

*Quality of Life: Expanded Prostate Cancer Index Composite (EPIC)* assesses prostate-specific quality of life (32 items with 4 subscales: urinary, bowel, sexual and hormonal function). It has greater coverage of key domains and sensitivity to treatment effects than previous prostate-specific quality of life measures.<sup>57</sup> It shows good test-retest reliability and internal consistency for all domain summary scores (each  $r > 0.80$  and Cronbach's  $\alpha > 0.82$ ).

*The Short-form Patient Satisfaction Questionnaire (PSQ-18)* consists of 18 items covering access, convenience, continuity, perceived communication between healthcare providers and technical competence).<sup>58</sup> It shows good internal consistency (each Cronbach's  $\alpha > 0.7$ ) and strong correlations with the original 50-item PSQIII.<sup>59</sup> After piloting in the phase I study, this scale has been modified to refer explicitly to the cancer follow-up care provided by hospital doctors and general practitioners during the previous 12 months.

*Preference for Follow-up Care (PFC)* Questions about preferences for future follow-up care have been adapted from the Cancer Survivors Follow-up Care Study (Adult Survivors Survey; personal communication A Girgis) A direct question about preference for specific type of follow-up care has also been included.

1  
2  
3  
4  
5  
6  
7 Participants complete the HADs, CaSUN and EPIC at four time points: prior to randomisation and  
8 then at 3, 6 and 12 months follow-up. Participants complete the PSQ-18 and PFC after their 12  
9 month follow-up appointment.

#### 10 11 *Clinical process measures*

12 The following clinical information will be collected from GP medical records and Medicare Australia  
13 data, including both Medical Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS)  
14 data:

- 15 a. Recurrence rates and detection: use of PSA according to protocol<sup>50</sup> and time to detect  
16 recurrence.
- 17 b. Mental health care: e.g. prescribing of antidepressants; referrals to clinical psychologists  
18 and use of specific Medicare Mental Health Care Plan items.
- 19 c. Detection and management of psychosexual adverse effects: e.g. prescribing of  
20 phosphodiesterase type-5 inhibitors and referrals to sexual health services.
- 21 d. Detection and management of other physical adverse effects of treatment: prescribing pre-  
22 specified drugs for urinary and bowel symptoms (e.g. oxybutynin, prazosin, loperamide,  
23 steroid enemas) and referrals to continence physiotherapy or urology.
- 24 e. Management of co-morbidities will be determined by pathology data for common tests  
25 performed in the management of common chronic disease (e.g. vascular disease and  
26 diabetes) and will include, for example, lipids and HbA1c. This is to assess whether the  
27 model of shared care has an effect on the management of other co-morbidities.
- 28
- 29
- 30
- 31
- 32

33 *Health care resource usage:* data will be collected regarding hospitalisations, visits to healthcare  
34 professionals, investigations and medications, predominantly through Medicare Australia (MBS and  
35 PBS) and GP record audit. Unit costs obtained from a variety of sources (e.g. Australian refined  
36 diagnosis-related groups, MBS and PBS) will be applied to the resource usage data collected within  
37 the trial to estimate the incremental cost of the shared care model versus standard care from a  
38 health service perspective.

39 *Trial feasibility:* as a phase II trial we will obtain data on patient eligibility, recruitment and attrition  
40 rates, GP recruitment and attrition rates, and response rates to outcome measures to inform  
41 decisions and planning for a larger phase III trial.

#### 42 43 *Sample size*

44 The study is designed to provide preliminary estimates of the feasibility and the efficacy of the  
45 shared care intervention for phase III planning purposes and does not employ a statistical hypothesis  
46 testing framework. The sample size is based on ensuring adequate information is collected to yield  
47 preliminary estimates of the treatment effect and of between-patient variation that are sufficiently  
48 precise for phase III trial planning purposes. The sample size target was revised at a steering  
49 committee meeting on 02 August 2012. This was in response to lower accrual rates than predicted,  
50 specifically due to a lower proportion of low-moderate risk prostate cancers than originally  
51 estimated. The revised target of 90 men was selected to ensure that the 95% confidence intervals  
52 for the mean difference between the two groups on the patient reported outcome measures would  
53 extend no further than +/- 0.5 of a standard deviation with 80% probability and allowing for 10%  
54 attrition at 12 months (i.e. complete data on N = 80 is required). This level of precision corresponds  
55

1  
2  
3  
4  
5  
6  
7 to what has been proposed as a minimal clinically important difference of health-related quality of  
8 life measures<sup>60</sup> allowing us to identify clinically significant harm from the intervention if it existed.  
9 Data from a trial of a group-based intervention involving 331 men with prostate cancer in Victoria,  
10 Australia ([P Schofield, in submission ACTRN12606000184572](#)) has been used to estimate how this  
11 level of precision will translate to estimates from the HADS and EPIC instruments.

12 Recruitment was completed in July 2013.

#### 14 Analyses

15 Baseline characteristics of the two arms will be described. Possible attrition bias will be assessed by  
16 comparing non-completion rates between treatment groups in conjunction with the baseline  
17 characteristics of those who withdraw or die against those who remain in the study.

18 *Estimating potential effect size and coefficient of variation:* Mean scores of HADS, CaSUN, EPIC and  
19 PSQ-18 will be compared between intervention and usual care groups. Mean differences between  
20 groups will be calculated with 95% confidence intervals at each follow-up time-point with and  
21 without adjusting for baseline score, site and treatment type (surgery and / or radiotherapy).  
22 Treatment groups will be compared on the categorical endpoints (e.g. clinical process measures)  
23 using chi-squared tests. Logistic regression modelling will also be undertaken to estimate the  
24 treatment effect on these endpoints adjusting for baseline covariates. The principal emphasis of the  
25 analysis will be on obtaining estimates of the treatment effect size and assessing feasibility in order  
26 to inform the design of a subsequent phase III trial. P-values for the multiple comparisons between  
27 the groups will be interpreted in this context.

#### 29 Discussion

30 The ProCare Trial has several novel elements: it is the first randomised controlled trial of a model of  
31 shared care for men with prostate cancer; it is the first trial to use the Distress Thermometer in  
32 primary care and the first to test a specific problem checklist to identify unmet needs of cancer  
33 survivors in primary care. We are testing a survivorship care plan (SCP) in primary care. One of the  
34 problems with the Grunfeld trial of SCPs in primary care was the high proportion of prevalent cancer  
35 cases who had completed treatment several years previously, and were possibly less likely to  
36 benefit.<sup>35 36</sup> We are therefore only recruiting men who have very recently completed their cancer  
37 treatment and in their first 12 months of follow-up care.

38 As a phase II trial it is designed to yield estimates of sufficient precision for phase III trial planning  
39 purposes. However, as with all trials of alternative models of cancer follow-up, an outstanding  
40 methodological issue is the selection of an appropriate primary outcome measure. Most trials have  
41 measured satisfaction with care and a range of health-related quality of life measures, finding no  
42 differences between hospital and primary care follow-up.<sup>23</sup> Trials in populations at low risk of cancer  
43 recurrence would need to be unfeasibly large to detect differences in survival. The ProCare Trial  
44 includes a range of outcome measures including disease-specific quality of life and unmet need. The  
45 intervention is designed to improve the identification of unmet needs and implement best practice  
46 management in the expectation that this will improve disease-specific quality of life and overall well-  
47 being.

48 We are recruiting men from a range of metropolitan and rural settings in two states in Australia  
49 including public and private healthcare settings. Based on discussions with urologists and radiation  
50 oncologists we have chosen only to recruit men with low-intermediate risk of disease recurrence,  
51 based on the D'Amico criteria.<sup>61</sup> As the first trial of shared follow-up care in prostate cancer it was  
52 agreed by the investigator team for safety reasons to focus initially on men with low-intermediate  
53 risk disease. This is also consistent with international approaches to risk stratified follow-up.<sup>62</sup> Our  
54  
55



1  
2  
3  
4  
5  
6  
7 trial population is likely to be representative of a wide range of men with low-intermediate risk  
8 prostate cancer who might be offered alternative follow-up arrangements if this model of care were  
9 shown to be feasible and acceptable.

10 We plan to complete follow-up in July 2014 and report trial results in early 2015.

### 11 **Ethics**

12 Ethics approval has been granted from the University of Western Australia's Human Research Ethics  
13 Committee (RA / 4/ 1/ 4447) as well as from all hospital recruitment sites in Western Australia and  
14 Victoria. The study has also been approved by the External Review Committee of the  
15 Commonwealth Department of Human Services to obtain Medicare Benefits Schedule and  
16 Pharmaceutical Benefits Schedule data from participants with their consent.

### 17 **Dissemination**

18 This is the first randomised controlled trial of a model of shared care for men with prostate cancer; it  
19 is also the first trial to use the Distress Thermometer in primary care and the first to test a specific  
20 checklist to identify unmet needs of cancer survivors in primary care. We plan to publish the main  
21 trial outcomes in a single paper and anticipate publishing additional papers exploring the data in  
22 more detail and relating to the implementation of this complex intervention. We will also present  
23 the findings at national and international conferences from late 2014.

### 24 **Author affiliations**

- 25 1. General Practice and Primary Health Care Academic Centre, The University of Melbourne
- 26 2. General Practice, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia
- 27 3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Victoria
- 28 4. Psycho-oncology Co-operative Research Group (PoCoG), School of Psychology, The University of Sydney
- 29 5. School of Surgery, The University of Western Australia
- 30 6. Urology Department, Fremantle Hospital, Western Australia
- 31 7. NHMRC Clinical Trials Centre, Sydney Medical School, The University of Sydney
- 32 8. School of Public Health, The University of Sydney
- 33 9. Genesis Cancer Care, Royal Perth Hospital, Western Australia
- 34 10. Prostate Cancer Foundation of Australia
- 35 11. Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Victoria
- 36 12. Urology Department, Royal Perth Hospital, Western Australia
- 37 13. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria
- 38 14. Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University

### 39 **Contributors**

40 JE coordinated the design, funding award and implementation of the study and led the writing of the  
41 manuscript.

42 JD coordinated the recruitment and data collection for the study and contributed to the writing of  
43 the manuscript.

44 MJ contributed to the design, funding award and implementation of the study and to the writing of  
45 the manuscript.

46 MK contributed to the design, funding award and implementation of the study and to the writing of  
47 the manuscript.

1  
2  
3  
4  
5  
6  
7 MP contributed to the study design, funding award and implementation of the study and to the writing of the manuscript.

8 DH contributed to the study design, funding award and implementation of the study in WA and contributed to the writing of the manuscript.

9  
10 AM contributed to the study design, funding award and statistical advice and contributed to the writing of the manuscript.

11  
12 LT contributed to the design, funding award and implementation of the study and to the writing of the manuscript.

13  
14 TL provided clinical expertise and was principal investigator at Royal Perth Hospital recruitment site; RC provided expertise from consumer perspective for study design, funding award and implementation of the study.

15  
16 CH undertook recruitment and data collection at Fremantle Hospital, WA

17  
18 AmH undertook recruitment and data collection for Victorian sites and approved the final manuscript.

19  
20 AkH was principal investigator at Royal Perth Hospital Urology Services, WA and approved the final manuscript.

21  
22 JV was principal investigator at Peter MacCallum Cancer Centre, Sunshine Hospital, Victoria and approved the final manuscript.

23  
24 SG was principal investigator at Peter MacCallum Cancer Centre, Bendigo Hospital, Victoria and approved the final manuscript.

25  
26 MF was principal investigator at Cabrini Hospital and Bairnsdale Hospital, Victoria and approved the final manuscript.

27  
28 PS contributed to the study design, funding award and implementation of the study in Victoria and to the writing of the manuscript.

29  
30

### 31 **Funding**

32 This trial is supported by the National Health and Medical Research Council (grant ID 1003414). Associate Professor Schofield and Associate Professor Pirotta are supported by National Health and Medical Research Council Career Development Fellowships. The funder will have no role in the analysis or dissemination of results.

Formatted: Font: Not Bold

### 36 **Competing interests**

37 None

### 38 **Acknowledgements**

39 This trial is supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

40  
41 We thank the following people who have also been involved in the establishment and conduct of this trial: Sharon Ray, Sema Cakan, Anna Ugalde, Rose Kamateros, Emily Habgood, Danielle Miller and Shona Silvester.

42  
43 We are grateful to all the trial participants, GPs and hospital specialists involved in the trial.

### 44 **References**

45  
46  
47  
48  
49  
50  
51 1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. *European urology* 2012;61(6):1079-92.

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International journal of cancer. Journal international du cancer* 2010;127(12):2893-917.
3. Cancer in Australia: an overview. Canberra: Australian Institute of Health and Welfare, 2012.
4. Cancer incidence projections: Australia, 2011-2020. Canberra: Australian Institute of Health and Welfare, 2012.
5. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009;27(17):2758-65.
6. SEER Stat Fact Sheets: Prostate Cancer: National Cancer Institute, 2013.
7. O'Brien R, Rose PW, Campbell C, Weller D, Neal RD, Wilkinson C, et al. Experiences of follow-up after treatment in patients with prostate cancer: a qualitative study. *BJU International* 2010;106(7):998-1003.
8. Boberg E, Gustafson D, Hawkins R, Offord K, Koch C, Wen K. Assessing the unmet information, support and care delivery needs of men with prostate cancer. *Patient Educ Counsel* 2003;49:233-42.
9. Ream E, Quennell A, Fincham L, Faithfull S, Khoo J, Wilson-Barnett J. Supportive care needs of men living with prostate cancer in England: a survey. *British Journal of Cancer* 2008;98:1903-09.
10. Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, et al. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. *New England Journal of Medicine* 2013;368(5):436-45.
11. Cockle-Hearne J, Charnay-Sonnek F, Denis L, Fairbanks HE, Kelly D, Kav S, et al. The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. *British journal of cancer* 2013;109(8):2121-30.
12. Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer. *J Clin Oncol* 2007;25(18):2560-6.
13. Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. *BMJ* 2009;339:b4817.
14. Khan NF, Watson E, Rose PW. Primary care consultation behaviours of long-term, adult survivors of cancer in the UK. *British Journal of General Practice* 2011;61(584):197-99.
15. Heins MJ, Korevaar JC, Rijken PM, Schellevis FG. For which health problems do cancer survivors visit their General Practitioner? *European journal of cancer* 2013;49(1):211-18.
16. The BEACH Project: Bettering the Evaluation and Care of Health Australian General Practice Statistics and Classification Centre, 2009.
17. Role Redesign Primary Care – Shared Care. Models of Cancer Treatment and Surveillance Post Treatment. Final Report. . In: Communications. GCA, editor. Canberra: Cancer Australia, 2010.
18. Pascoe SW, Neal RD, Allgar VL, Selby PJ, Wright EP. Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. *Fam Pract* 2004;21(4):437-42.
19. Richards M, Corner J, Maher J. The National Cancer Survivorship Initiative: new and emerging evidence on the ongoing needs of cancer survivors. *British journal of cancer* 2011;105 Suppl 1:S1-4.
20. Prostate cancer: diagnosis and treatment. London: National Institute of Clinical Excellence, 2008.
21. Lewis RA, Neal RD, Williams NH, France B, Hendry M, Russell D, et al. Follow-up of cancer in primary care versus secondary care: systematic review. *The British journal of general practice : the journal of the Royal College of General Practitioners* 2009;59(564):e234-47.
22. Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. *British journal of cancer* 2010;102(10):1447-55.

23. Emery JD, Trevena L, Mazza D, Fallon-Ferguson J, Shaw K, Williams B, et al. The role of primary and community-based healthcare professionals in early detection and follow-up of cancer: a rapid review of best practice models. Sydney, NSW: Sax Institute, 2013.
24. Emery JD, Shaw K, Williams B, Mazza D, Fallon-Ferguson J, Varlow M, et al. The role of primary care in early detection and follow-up of cancer. *Nature reviews. Clinical oncology* 2014;11(1):38-48.
25. Taggart F, Donnelly P, Dunn J. Options for early breast cancer follow-up in primary and secondary care - a systematic review. *BMC cancer* 2012;12:238.
26. Gunn JM, Palmer VJ, Naccarella L, Kokanovic R, Pope CJ, Lathlean J, et al. The promise and pitfalls of generalism in achieving the Alma-Ata vision of health for all. *Med J Aust* 2008;189(2):110-2.
27. Grunfeld E, Earle C. The Interface Between Primary and Oncology Speciality Care: Treatment Through Survivorship. *J Natl Cancer Inst. Monographs* 2010(40):25-30.
28. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington DC, 2006.
29. Hodgkinson K, Butow P, Hobbs KM, Wain G. After cancer: the unmet supportive care needs of survivors and their partners. *J Psychosoc Oncol* 2007;25(4):89-104.
30. McIntosh HM, Neal RD, Rose P, Watson E, Wilkinson C, Weller D, et al. Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines. *Br J Cancer* 2009;100(12):1852-60.
31. Jiwa M, Saunders CM, Thompson SC, Rosenwax LK, Sargant S, Khong EL, et al. Timely cancer diagnosis and management as a chronic condition: opportunities for primary care. *Med J Aust* 2008;189(2):78-82.
32. Walsh J, Harrison JD, Young JM, Butow PN, Solomon MJ, Masya L. What are the current barriers to effective cancer care coordination? A qualitative study. *BMC Health Services Research* 2010;10.
33. Chen Y, Brennan N, Magrabi F. Is email an effective method for hospital discharge communication? A randomized controlled trial to examine delivery of computer-generated discharge summaries by email, fax, post and patient hand delivery. *Int J Med Inform.*
34. Jefford M, Baravelli C, Dudgeon P, Dabscheck A, Evans M, Moloney M, et al. Tailored chemotherapy information faxed to general practitioners improves confidence in managing adverse effects and satisfaction with shared care: results from a randomized controlled trial. *J Clin Oncol* 2008;26(14):2272-7.
35. Grunfeld E, Julian J, Pond G, Maunsell E, Coyle D, Folkes A, et al. Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. *Journal of Clinical Oncology* 2011;29(36):4755-62.
36. Jefford M, Schofield P, Emery J. Improving survivorship care. *Journal of Clinical Oncology* 2012;30(12):1391-92.
37. Brown RF, Butow PN, Sharrock MA, Henman M, Boyle F, Goldstein D, et al. Education and role modelling for clinical decisions with female cancer patients. *Health Expect* 2004;7(4):303-16.
38. Barlow J, Wright C, Sheasby J. Self-management approaches for people with chronic conditions: a review. *Patient Educ Counsel* 2002;48:177-87.
39. Deadman J, Leinster S, Owens R. Taking responsibility for cancer treatment. *Soc Sci Med* 2001;53:669-77.
40. Cockle-Hearne J, Faithfull S. Self-management for men surviving prostate cancer: a review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. *Psycho-oncology* 2010;19(9):909-22.
41. Griffin SJ, Kinmonth AL, Veltman MW, Gillard S, Grant J, Stewart M. Effect on health-related outcomes of interventions to alter the interaction between patients and practitioners: a systematic review of trials. *Ann Fam Med* 2004;2(6):595-608.


- 1  
2  
3  
4  
5  
6  
7 42. Dimoska A, Tattersall MH, Butow PN, Shepherd H, Kinnersley P. Can a "prompt list" empower  
8 cancer patients to ask relevant questions? *Cancer* 2008;113(2):225-37.
- 9 43. Jefford M, Karahalios A, Angle A. Understanding issues for cancer survivors: informing the  
10 development of a written information booklet. *Psychooncology* 2007;16 S273.
- 11 44. Ryan P, Lauver DR. The efficacy of tailored interventions. *J Nurs Scholarsh* 2002;34(4):331-7.
- 12 45. Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, et al. Main outcomes  
13 of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention  
14 among breast and prostate cancer survivors. *Journal of clinical oncology : official journal of  
15 the American Society of Clinical Oncology* 2007;25(19):2709-18.
- 16 46. Developing and evaluating complex interventions: new guidance. London: Medical Research  
17 Council., 2008.
- 18 47. Campbell N, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F, et al. Designing and evaluating  
19 complex interventions to improve healthcare. *BMJ* 2007;334:455-59.
- 20 48. Jacobsen P, Donovan K, Trask P. Screening for psychologic distress in ambulatory care patients.  
21 *Cancer* 2005;103:1494-502.
- 22 49. Localised prostate cancer: a guide for men and their families. : Andrology Australia & Australian  
23 Prostate Cancer Collaboration. , 2009.
- 24 50. Heidenreich A, Bolla M, Joniau S, Kwast THvd, V. Matveev, Mason MD, et al. Guidelines on  
25 prostate cancer: European Association of Urology, 2009.
- 26 51. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving Chronic Illness  
27 Care: Translating Evidence Into Action. *Health Affairs* 2001;20:64-78.
- 28 52. Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*  
29 1983;67:361-70.
- 30 53. Bjellanda I, Dahlb A, Haugc T, Neckelmann D. The validity of the Hospital Anxiety and Depression  
31 Scale. An updated literature review. *Journal of Psychosomatic Research* 2002; 52:69- 77.
- 32 54. Lockett T, Butow PN, King MT, Oguchi M, Heading G, Hackl NA, et al. A review and  
33 recommendations for optimal outcome measures of anxiety, depression and general distress  
34 in studies evaluating psychosocial interventions for English-speaking adults with  
35 heterogeneous cancer diagnoses. *Supportive care in cancer : official journal of the  
36 Multinational Association of Supportive Care in Cancer* 2010;18(10):1241-62.
- 37 55. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Lo SK, et al. The development and  
38 evaluation of a measure to assess cancer survivors' unmet supportive care needs: the CaSUN  
39 (Cancer Survivors' Unmet Needs measure). *Psychooncology* 2007;16(9):796-804.
- 40 56. Schofield P, Gough K, Lotfi-Jam K, Aranda S. Validation of the Supportive Care Needs Survey—  
41 short form 34 with a simplified response format in men with prostate cancer. *Psycho-  
42 Oncology* 2012;21(10):1107-12.
- 43 57. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the  
44 expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-  
45 related quality of life in men with prostate cancer. *Urology* 2000;56(6):899-905.
- 46 58. Marshall G, Hays R. The patient satisfaction questionnaire short-form (PSQ-18): RAND  
47 Corporation, 1994.
- 48 59. Ware JE, Jr., Davies-Avery A, Stewart AL. The measurement and meaning of patient satisfaction.  
49 *Health Med Care Serv Rev* 1978;1(1):1, 3-15.
- 50 60. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the  
51 remarkable universality of half a standard deviation. *Medical care* 2003;41(5):582-92.
- 52 61. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. *Oncology*  
53 2001;15(8):1049-59; discussion 60-2, 64-5, 69-70,73-5.
- 54 62. Watson EK, Rose P, Neal RD, Hulbert-Williams N, Donnelly P, Hubbard G, et al. Personalised  
55 cancer follow-up: risk stratification, needs assessment or both? *British journal of cancer*  
56 2012;106:1-5.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



BMJ Open: first published as 10.1136/bmjopen-2014-004972 on 6 March 2014. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

Figure 1. Trial flowchart



90x127mm (300 x 300 DPI)